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RP-HPLC  Reverse phase high performance liquid chromatography 
UV   Ultra Violet 
HPTLC                       High performance thin layer chromatography  
nm   Nanometer 
Rt   Retention time 
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ICH   International conference harmonization 
CV   Correlation coefficient 
%   Percentage 
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ng   nanogram 
ml   milliliter 
v/v   volume by volume 
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min   minutes 
MET                            Metformin 
ALO                            Alogliptin 
LC-MS                        Liquid chromatography- Mass spectroscopy 
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PDA                            Photo diode array detector  
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INTRODUCTION 
Pharmaceutical Analysis 
 Pharmaceutical analysis determines the quality of drug products via analytical 
chemistry. This will introduce areas such as method validation, handling of raw materials and 
finished products, documentations, inspections that impact the development of 
pharmaceutical products. 
          Throughout this, critical cGMPs regulations, FDA guidance and ICH quality guidelines 
will be discussed specially emphasizing procedures to help individuals to maintain a high 
level of compliance that rounds the laboratory environment. 
 
Importance of pharmaceutical analysis 
 Identify of the drug in formulated product  
 Determination of active ingredient or additional impurities  
 Stability of the drug  
 Rate of drug from its formulation  
 Identify and purity of pure drug that meet specification  
 Concentration of specified impurities 
 Concentration of drug in plasma or biological fluids  
 Determine pka values partition coefficients, solubilities and stability of drug under                                                  
development. 
 Chemistry 
 Chemistry is the study of matter including its composition, structure, physical 
properties and reactivity. There are many approaches to studying chemistry. They were 
divided into five fields. 
               They were divided into five fields 
1. Organic chemistry 
2. Inorganic chemistry 
3. Physical chemistry 
4. Biochemical chemistry 
5. Analytical chemistry 
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Analytical chemistry 
 Analytical chemistry is the study of separation, identification and quantification of the 
chemical components of natural and artificial materials. 
Qualitative analysis 
 Qualitative analysis gives an indication of the identify of the chemical species in the 
sample. 
Quantitative analysis 
 Quantitative analysis determines the amount of one (or) more of there components. 
The separation of the component is often performed prior to analysis. 
Analytical perspective 
        Perspective as an analytical approach to solving problems. 
 Identify and define the problem 
 Design the experimental procedure 
 Conduct an experiment and gather data 
 Analyse the experiment data 
 Propose a solution to the problem 
Analytical methods 
 Analytical methods are divided into two types [3] 
 
 
 
Analytical methods
Classical method
It's uses separation such as 
1.precipitation
2.Extarction
3.Distillation
Instrumental 
method
It's  uses an apparatus to measure
1.Fluorimetry
2. spectroscopy
3. Infra red spectroscopy
4.Chromatography
5.polarography
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Instrumental method 
 It’s use an apparatus to measure physical quantities of the analyte such as light 
absorption, fluorescence and conductivity. Analytical measurements are made using 
instruments.  
Characteristic properties Instrumental methods 
Emission of radiation Emission spectroscopy, fluorescence, 
Phosphorescence and luminescence  
Absorption of radiation Spectrometry, Photometry, Nuclear magnetic 
resonance spectroscopy and Electron spin resonance 
spectroscopy, infra red spectroscopy 
Scattering of radiation Turbidimetry and Raman spectrometry  
Refraction of radiation Refractometry 
Electrical current Amperometry, polarography 
Mass to charge ratio Mass spectrometry 
Electrical potential Polarography 
 
Application of instrumental methods 
1. Bioanalytical: 
Biological molecules and/or biological matrices (e.g. proteins, amino acids, 
blood, urine) 
2. Environmental: 
Pesticides, pollution, air, water, soil. 
3. Material science: 
Polymers, Characterisation of new materials. 
4. Forensic science: 
           Body fluids, DNA, Hair fibres, Elemental analysis, Drugs and Alcohols. 
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SPECTROSCOPY 
Spectroscopy  is  the  branch of  science  that  deals  with  the  interaction  between  
ELECTROMAGNETIC RADIATION and MATTER. 
Principles of spectroscopy 
 The principle is based on the measurement of spectrum of sample containing            
atoms/molecules. Spectrum is the graph of intensity of absorbed or emitted radiation 
by sample Vs frequency or wavelength.[3] 
Types of Spectroscopy 
1. Absorption spectroscopy 
An analytical technique which concerns with the measurement of absorption of 
electromagnetic radiation. 
Eg: UV (185-400nm)/ VISIBLE (400-800nm) spectroscopy 
2. Emission spectroscopy 
An analytical technique which emission & the amount of dispersion is measured. 
Eg: Flame emission spectroscopy 
ULTRAVIOLET AND VISIBLE SPECTROSCOPY 
        Ultraviolet (UV) spectroscopy is a physical technique of the optical spectroscopy that 
uses light in the visible, ultraviolet, and near infrared ranges. The Beer-Lambert law states 
that the absorbance of a solution is directly proportional to the concentration of the absorbing 
species in the solution and the path length. Thus, for a fixed path length, UV/VIS 
spectroscopy can be used to determine the concentration of the absorber in a solution. It is 
necessary to know how rapidly the absorbance changes with concentration. 
Principle of Ultraviolet and Visible Spectroscopy 
        A molecule or ion will exhibit absorption in the visible or ultraviolet region when 
radiation causes an electronic transition within its structure. Thus, the absorption of light by a 
sample in the ultraviolet or visible region is accompanied by a change in the electronic state 
of the molecules in the sample. The energy supplied by the light will promote electrons from 
their ground state orbitals to higher energy, excited state orbitals or antibonding orbitals.  
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Potentially, three types of ground state orbitals may be involved: 
1. σ (bonding) molecular  
2. π (bonding) molecular orbital  
3. n (non-bonding) atomic orbital In addition, 
 Two types of antibonding orbitals may be involved in the transition: 
i) σ* (sigma star) orbital  
ii) ii) π* (pi star) orbital  
(There is no such thing as an n* antibonding orbital as the n electrons do not form bonds). 
Ultraviolet Absorption Spectrophotometry  
         Spectrophotometry is generally preferred especially by small-scale industries as the 
cost of the equipment is less and the maintenance problems are minimal. The method of 
analysis is based on measuring the absorption of a monochromatic light by colourless 
compounds in the near ultraviolet path of spectrum (200-380nm). The photometric methods 
of analysis are based on the Bouger-Lambert-Beer’s law, which establishes that the 
absorbance of a solution is directly proportional to the concentration of the analyte.  
        The fundamental principle of operation of spectrophotometer covering UV region 
consists in that light of definite interval of wavelength passes through a cell with solvent and 
falls on to the photoelectric cell that transforms the radiant energy into electrical energy 
measured by a galvanometer. Ultraviolet visible spectroscopy is used to obtain the 
absorbance spectra of a compound in solution or as a solid. What is actually being observed 
spectroscopically is the absorbance of light energy or electromagnetic radiation, which 
excites electrons from the ground state to the first singlet excited state of the compound or 
material. The UV-visible region of energy for the electromagnetic spectrum covers 1.5 - 6.2 
eV which relates to a wavelength range of 800 - 200 nm. 
        The Beer-Lambert Law (Equation1) is the principle behind absorbance spectroscopy. 
For a single wavelength, A is absorbance (unit less, usually seen as arb. units or arbitrary 
units), is the molar absorptivity of the compound or molecule in solution (M-1cm-1), b is the 
path length of the cuvette or sample holder (usually 1 cm), and c is the concentration of the 
solution (M).  
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A = a b c  
Where,  
A = Absorbance,  
a = absorptivity,  
b = path length,  
c = concentration.  
     C = A /a b 
There are three types of absorbance instruments used to collect UV-Visible spectra: 
 1. Single beam spectrometer.  
2. Double beam spectrometer.  
          All of these instruments have a light source (usually a deuterium or tungsten lamp), a 
sample holder and a detector, but some have a filter for selecting one wavelength at a time. 
The single beam instrument has a filter or a monochromator between the source and the 
sample to analyze one wavelength at a time. The double beam instrument has a single source 
and a monochromator and then there is a splitter and a series of mirrors to get the beam to a 
reference sample and the sample to be analyzed, this allows for more accurate 
monochromator between the sample and the source. Instead, it has a diode array detector that 
allows the instrument to simultaneously detect the absorbance at all wavelengths. The 
simultaneous instrument is usually much faster and more efficient, but all of these types of 
spectrometers work well. 
Multicomponent analysis is pharmaceutical dosage forms by UV spectrophotometry 
           The spectroscopic assay of drug rarely involves the measurement of absorbance of 
samples containing only one absorbing component. The pharmaceutical analyst frequently 
encounters the situation where the concentration of the or more substances is required in 
samples known to contain  other absorbing substances which  potentially interfere  in  the 
assay it the formula of the samples  is known  of  the samples  is  known the  identify  and 
concentration of  the  interfere  are known and the extent of interference in assay may be 
determined. 
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Some of the commonly used spectrophotometric methods are as follows  
1. Simultaneous equation method (vierdott’s method) 
2. Derivative spectrometric method 
3. Absorbance ratio method(Q-Absorbance method) 
4. Solvent extraction method 
5. Dual wavelength method 
6. Geometric correction method 
7. H.point standard addition method 
8. Least square approximation method 
SIMULTANEOUS EQUATION METHOD 
If a sample contain two absorbing drugs (X &Y) each of this absorbs at the λmax of each 
other, it may be possible to determine both the drugs by the technique of   simultaneous 
equations (vierodt’s method) provided that certain criteria apply. 
The information required is: 
(a) the absorptivities of X at λ1 and λ2, ax1 and ax2 respectively 
(b) the absorptivities of Y at λ1 and λ2, ay1 and ay2 respectively 
(c) the absorbance of the diluted sample at λ1 and λ2, A1 and A2 respectively. 
Let cx & cy be the concentrations of X & Y respectively in the diluted sample.  
Two equations are constructed based upon the fact that at λ1 and λ2 the absorbance of the 
mixture is the sum of the individual absorbances of X&Y. 
At λ1                       A1= ax1bcx + ay1bcy --------------1 
At λ2                      A2= ax2bcx + ay2bcy--------------2 
For measurements in 1cm cells, b=1. 
Rearrange the eq. (2). 
  A2 – ax2cx 
               cy =        
    ay2 
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Substituting for Cy in eq. (1) and rearranging gives  
      A2 ay1 – A1 ay2 
                  cx =  
   ax2 ay1 –ax1 ay2 
and 
  A1 ax2 – A2 ax1 
                cy =  
ax2 ay1 – ax1 ay2 
Criteria for obtaining maximum precision based upon the absorbance ratio have been 
suggested that place limit on the relative concentration of the components of the mixture. 
The criteria are that of the ratio  
 A2/A1          and     ay2 / ay1 
           ax2/ ax1            A2/A1 
 
          Where,  
cx and cy are the concentrations of X and Y. 
ax1 and ax2 are absorptivities of X. 
ay1 and ay2 are absorptivities of  Y. 
  A1 and A2 absorbances of mixture. 
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Chromatography  
            Chromatography is the powerful techniques in which differential migration of 
components takes place between two phases, one is stable which is known as stationary phase 
and another is movable which is known as mobile phase. Species in the sample undergo 
repeated interaction (partition) between the mobile phase and stationary phase.  
          Chromatographic method must having essentially,  
 Stationary phase 
 Mobile phase 
 Sample injection system 
 Solvent delivery system 
 Column (support for stationary phase) 
 Detection by detecting agent 
  Classification of chromatographic methods 
 Chromatography 
  
    Gas chromatography                                 Liquid chromatography 
                          
Gas- liquid chromatography    Gas – solid chromatography 
 
          Liquid-liquid chromatography    Liquid-solid chromatography    Ion exchange chromatography   
  Types of chromatography (Based on nature) 
                        Chromatography 
     
Adsorption                    Partition                       Ion-exchange                    Size-exclusion 
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Chromatography (Based on separation) 
 
                     Chromatography 
      
Normal phase                          Reverse phase                                             Affinity 
HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY 
 High performance thin layer chromatography is the most powerful advanced form of 
Thin Layer Chromatography (TLC) and consists of chromatographic layers of utmost 
separation efficiency and the application of sophisticated instrumentation for all steps in the 
procedure include accurate sample application, standardized reproducible chromatogram 
development and software controlled evaluation.    
Advantages of HPTLC 
 The separation process is easy to follow especially with colored compounds. 
 Choice of solvents for HPTLC method development is wide as the mobile 
phases are fully evaporated before the detection step. 
 Two- dimensional separations are easy to perform. 
  HPTLC can combine and consequently be used for different modes of 
evaluation, allowing identification of compounds having different light 
absorption characteristics or different colours. 
 HPTLC method may help to minimizes exposure risk of toxic organic 
effluents and significantly reduces its disposal problems, consequently reduces 
environmental pollution. 
Principle of HPTLC 
 HPTLC have similar approach and employ the same physical principles of TLC 
(adsorption chromatography) i.e. the principle of separation is adsorption.  
 The mobile phase solvent flows through because of capillary action. The components 
move according to their affinities towards the adsorbent. The component with more affinity 
towards the stationary phase travels slower. The component with lesser affinity towards the 
stationary phase travels faster. Thus the components are separated on a chromatographic 
plate.  
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Classification of HPTLC 
 HPTLC techniques may be classified into four classes. They differ with classical TLC in the 
particle size, distribution and thickness of sorbent layers. 
 
   
 
 
         
                                                              
 
 
Methodology for HPTLC Analysis 
 Method development in thin- layer (planar) chromatography is one of the most 
significant steps for a qualitative and quantitative analysis. During establishing a new 
analytical procedure, always starts with wide literature survey i.e. primary information about 
the physicochemical properties of the sample and nature sample (structure, polarity, 
volatility, stability and solubility). It involves considerable trial and error procedures. General 
steps involved in HPTLC method development are as follows; 
Basic steps: 
 Selection of the stationary phase  
 Mobile phase selection and optimization 
 Sample preparation and Application  
 Chromatogram development (separation) 
 Detection 
Selection of stationary phase 
 During method development, stationary phase selection should be based on the type 
of compounds to be separated. HPTLC uses smaller plates (10*10 or 10*20 cm) with 
significantly decreased development distance (typically 6 cm) and analysis time (7-20 mins). 
HPTLC plates provide improved resolution, higher detection sensitivity and improved in situ 
quantification and are used for industrial pharmaceutical densitometric quantitative analysis. 
HPTLC TECHNIQUES 
HIGH PERFORMANCE 
Particle size 5 µm 
Layer thickness200 µm 
      ULTRA 
Particle size 1-2 µm 
Layer thickness 10 µm 
 
    PREPARATIVE 
Particle size 25 µm 
Layer thickness 0.5-2 mm 
CLASSICAL 
Particle size 12 µm 
Layer thickness 250 
µm 
 
 
µm 
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Mobile phase selection and optimization 
 The selection of mobile phase is based on adsorbent material used as stationary phase 
and physical and chemical properties of analyte. Mobile phase for HPTLC method is selected 
and optimized on the basis of analyst’s own experience, literature report of similar studies 
and traditional trial and error method. CAMAG laboratory suggested four levels of 
techniques for mobile phase selection and optimization.  
First level involves the use of neat solvents (seven to twelve) and then by finding such 
solvents which can have average separation power of the desired drugs (optimization stops 
here if the analytical goal is achieved). Further, at this level the solvents are categorised on 
the basis of Rf value they produce: 
 Group A – solvents produce suitable Rf value (0.2< Rf<0.8), 
 Group B – solvent produces Rf value higher than 0.8 
 Group C – solvents produces Rf value less than 0.2 
Second level involves decreasing or increasing solvent strength using hexane or water 
for respective purposes. 
Third level involves trying of mixtures instead of neat solvents from the selected 
solvents of first and/or second level which can further be optimized by the use of modifier, 
such as acids or bases. 
If the Rf values are acceptable, go for level four, which includes, minor adjustment to 
the solvent strength, use of modifiers to improve the shape of the separated zones and 
alteration of chamber saturation time. If the separated zones show tailing, try adding 0.5 to 
1.0% water. Try exchanging acid or base for a weaker/stronger one. 
Sample Preparation and Application 
 A good solvent system is one of that moves all components of the mixture off 
baseline, but does not put anything on the solvent front. The peaks of interest should be 
resolved between Rf 0.15 and 0.85. The elution power of the mobile phase depends on a 
property called eluent strength which is related to the polarity of the mobile phase 
components. The more nonpolar compounds, the faster it will elute (or the less time it will 
remain on the stationary phase) and the more polar compound slower it will elute (or more 
time on the stationary phase). Pharmaceutical preparation with sufficiently high concentration 
of analyte is simply dissolved in a suitable solvent that will completely solubilise the analyte 
and leave excipients undissolved to yield a test solution that can be directly applied on 
HPTLC plate. It is a fact that application of the sample is the most critical step to obtain good 
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resolution for quantification in HPTLC. Sample application technique depends on factors 
such as the type of sample matrix, workload and time constraints. 
 
Chromatogram development 
 Although chromatogram development is the most crucial step in the HPTLC 
procedure, important parameters are generally overlooked. HPTLC plates are developed in 
twin-trough chambers, or horizontal- development chambers. In general, saturated twin 
trough chambers fitted with filter paper offer the best reproducibility. Twin trough chamber 
avoids solvent vapour preloading and humidity. 
 
Detection 
 Detection of separated compounds on the sorbent layers is enhanced by quenching of 
fluorescence due to UV light (ranged normally at 200-400 nm). This process is commonly 
called fluorescence quenching. 
Visualization at UV 254 nm 
 F254 should be described as phosphorescence quenching. In this instance the 
fluorescence remains for a short period after the source of excitation is removed. It is very 
short lived, but longer than 10 seconds. F254 fluorescent indicator is excited with UV 
wavelength at 254 nm and emits green fluorescence. Compounds that absorb radiation at 254 
nm reduce the emission on the layer and a dark violet spot on a green background is observed 
where the compound where the components zones are located. 
Visualization at UV 366 nm 
 F366 should be described as fluorescence quenching. In this instance the fluorescence 
dose not remains after the source of excitation is removed. 
 
Visualization at white light 
 Zone containing separated compounds can be detected by viewing their natural colour 
in daylight (white light).      
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BIOANALYSIS  
 Bioanalysis is the method used to determine the concentration of drugs, their 
metabolites and/or endogenous substance in the biological matrices such as blood, plasma, 
cerebrospinal fluid, urine and saliva. 
Reasons for developing new method of Bioanalysis 
 There may not be a suitable method for a particular analyte in the specific 
sample matrix. 
 Existing method may be too error (or) contamination prone (or) they may be 
unreliable. 
 Existing method may be too expensive, time consuming (or) energy intensive 
(or) they may not be easily automated. 
 Existing method may not provide adequate sensitivity (or) analyte selectivity 
in sample of interest. 
   Newer instrumentation and techniques may have evolved that provide 
opportunities for improved methods including improved analyte identification 
(or) detection limits, greater accuracy (or) precision or better return on 
investment. 
 There may be need for an alternative method to confirm, for legal (or) 
scientific reasons, analytical data originally obtained by existing method.   
Bioanalytical method 
 Bioanalytical method is a set of procedures involved in the collection, processing, 
storage and analysis of a biological matrix for a chemical compound. 
Separation of analyte 
            Extraction procedures for drugs and metabolites from biological samples: 
            Extraction of drug from biological matrix is traditionally carried out by 
a) Liquid-Liquid Extraction(LLE) 
b) Solid Phase Extraction (SPE) 
c) Precipitation of plasma Proteins (pp) 
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(a) Liquid-Liquid Extraction 
                  LLE is a method used for the separation of compounds in a mixture using water 
and an immiscible organic solvent. Separation of analyte occurs based on its partition co-
efficient between two immiscible liquids and extraction can be done by using suitable 
solvent. LLE method is simple, rapid and relatively cost effective compare to other 
techniques. Most of the drug can be recovered to the extent of 90% by multiple continuous 
extraction technique. 
                  First dissolve the components mixture in a suitable solvent and add immiscible 
solvent. Thoroughly mix and set aside. Separation of immiscible solvent into layers. The 
components of mixture distributed among the solvents based on their partition co-efficient. 
Separate the two layers transfer and isolate. The non-polar analyte extracted into organic 
phase and it’s easily recovered by evaporation. Then the residue reconstitute with a small 
volume of mobile phase. 
(b) Solid Phase Extraction 
                  SPE is a common and effective technique for isolation and concentration of 
analyte in trace amounts in a variety of sample matrices. With SPE the level of interferences 
can be reduced and final sample volume is minimized to maximize analyte sensitivity. Higher 
recovery of analyte can be obtained by using a small plastic disposable column or cartridge 
packed with 0.1 to 0.5 g of sorbent which is commonly RP material (C18 or C8). The 
components of interest may either preferentially adsorbed to the solid or they may remain in 
the liquid phase. If the desired analyte is adsorbed on the solid phase, it can be selectively 
desorbed by washing with an appropriate solvent. If the component of interest remains in a 
liquid phase, it can be recovered through concentration, evaporation and or crystallization. 
(c) Protein Precipitation 
                   Protein precipitation is a very simple technique for extraction of the analyte from 
the blood (or) plasma. The main requirement for this technique is that the analyte should be 
freely soluble into reconstituting solvent. In this technique, the sample is prepared by protein 
precipitation. Sample is treated with the acids (trichloroacetic acid, perchloric acid)/ Organic 
solvents (Methanol, Ethanol and acetone)/ Salts (ammonium sulphate). After precipitation the 
sample is centrifuged, analyte gets into supernatant. The supernatant liquid is injected into the 
HPLC.  
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HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
         HPLC method development and validation plays an important role in the discovery, 
manufacturing, development of pharmaceutical products. HPLC methods are able to separate, 
detect and quantify various drugs their related substances, degraded products and impurities 
that may be introduced during the synthesis of drug substances.      
        Biological matrices contain high concentrations of various endogenous substances and 
drug concentrations are often low. Sometimes the endogenous compounds are structurally 
similar to the drug to be estimated. For analysis, the drug must be isolated in pure state using 
a suitable extraction technique. Invention of modern analytical instruments and extraction 
techniques resulted in advanced bio analytical method development and validation. 
         High performance liquid chromatography (HPLC) is useful in identification and 
quantitative determination of drugs and metabolites in biological fluids, particularly plasma, 
serum or urine. HPLC require good selection of detectors, good stationary phase, Eluents and 
adequate program during separation. UV/VIS, PDA detectors are the most versatile detector 
used in HPLC. The main advantages of these chromatographic principles include low 
detection limits, the ability to generate structural information the requirement of minimal 
sample treatment and the possibility to cover a wide range of analytes differing in their 
polarities. 
Advantages of HPLC 
 Speed (analysis can be accomplished in 20 minutes or less)
 Greater sensitivity (various detectors can be employed)
 Improved resolution (wide variety of stationary phases)
 Reusable columns (expensive columns but can be used for many analysis)
 Ideal for the substances of low volatility
 Easy sample recovery, handling and maintenance
 Instrumentation tends itself to automation and quantitation (less time and less labour)
 Precise and reproducible,
 Calculations are done by integrator itself
 Suitable for preparative liquid chromatography on a much larger scale.

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Normal phase mode 
The stationary phase is polar and the mobile phase is nonpolar in nature. In this technique, 
nonpolar compounds travel faster and are eluted first. This is because of the lower affinity 
between the nonpolar compounds and the stationary phase. Polar compounds are retained for 
longer times because of their higher affinity with the stationary phase. These compounds, 
therefore take more times to elute. Normal phase mode of separation is therefore, not 
generally used for pharmaceutical applications because most of the drug molecules are polar 
in nature and hence take longer time to elute. 
Reversed phase mode  
It’s the most popular mode for analytical and preparative separations of compound of interest 
in chemical, biological, pharmaceutical, food and biomedical sciences. In this mode, the 
stationary phase is nonpolar hydrophobic packing with octyl or octa decyl functional group 
bonded to silica gel and the mobile phase is polar solvent. An aqueous mobile phase allows 
the use of secondary solute chemical equilibrium (such as ionization control, ion suppression, 
ion pairing and complexation) to control retention and selectivity. The polar compound gets 
eluted first in this mode and nonpolar compounds are retained for longer time. As most of the 
drugs and pharmaceuticals are polar in nature, they are not retained for longer times and 
hence elute faster. The different columns used are octa decyl silane (ODS) or C18, C8, C4, 
etc., (in the order of increasing polarity of the stationary phase). 
 
Principle 
 Principle is the solution of sample is injected into a column of porous material (stationary 
phase) and liquid phase (mobile phase) is pumped at higher pressure through the column. The 
principle of separation followed is the adsorption of solute on stationary phase based on its 
affinity towards stationary phase. 
Method development on HPLC 
 Steps involved in the HPLC method development is as follows 
 Understanding the physicochemical properties of drug molecule 
 Selection of chromatographic conditions 
 Developing the approach of analysis 
 Sample preparation 
 Method optimization 
 Method validation 
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Instrumentation 
          Components of HPLC are 
(a) Solvent delivery system including pump  
(b) Sample injection system 
(c) Chromatographic column 
(d) Detector 
(e) Chart recorder 
(f) Data handling device and microprocessor control 
 
(a) Solvent delivery system  
A mobile phase is pumped under pressure from one or several reservoir and 
flows through the column at a constant rate. For normal phase separation- 
eluting power increases with increasing polarity of the solvent but for reverse 
phase separation, eluting power decreases with increasing polarity. A degasser 
is needed to remove dissolved air and other gases from the solvent. Special 
grades of solvents are available for HPLC and these have been purified 
carefully in order to remove absorbing impurities and particulate matter to 
prevent these particles from damaging the pumping or injection system or 
clogging the column.   
     Pumps 
 The pump is one of the most important components of HPLC. Since its performance 
directly affects retention time, reproducibility and detector sensitivity. Three main 
types of pumps are used in HPLC to propel the liquid mobile phase through the 
system. These are;   
 
1. Displacement pump 
It produces a flow that tends to independent of viscosity and backpressure and also 
output is pulse free. But its possesses limited capacity (250ml). 
2. Reciprocating pump 
It has small internal volume (35 to 400 μl), their high output pressure (up to 10,000 
psi) and their constant flow rates, but it produces a pulsed flow. 
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3. Pneumatic or constant pressure pump: 
They are pulse free, suffer from limited capacity as well as dependence of flow rate 
on solvent viscosity and column backpressure. They are limited to pressure less than 
2000 psi.  
(b). Sample injection system 
Insertion of the sample onto the pressurised column must be as a narrow plug so that    
the peak broadening attributable to this step is negligible. The injection system itself 
should have no dead (void) volume. 
These are three important ways of introducing the sample into injection port: 
 Loop injection: In which, a fixed amount of volume is introduced by making use of 
fixed volume loop injector. 
 Valve injection:  In which, a variable volume is introduced by making use of an 
injection valve. 
 On column injection: In which, a variable volume is introduced by means of a syringe 
through a septum.   
(c). Chromatographic column: 
         The column is usually made up of heavy glass or stainless steel tubing to withstand                       
high pressure. The columns are usually 10-30 cm long and 4-10 mm inside diameter 
containing stationary phase at particle diameter of 25 µm or less. Columns with an 
internal diameter of 5 mm give good results because of compromise between 
efficiency, sample capacity and the amount of packing and solvent required. 
Column packing 
The packing used in modern HPLC consists of small, rigid particles having a narrow particle 
size distribution. There are three main types of column packing in HPLC. 
1. Porous, polymeric beds 
Porous, polymeric beds based on styrene divinyl benzene co polymers used in ion 
exchange and size exclusion chromatography. For analytical purpose these have now 
been replaced by silica based, packing which are more efficient and more stable. 
2. Porous layer beds 
Consisting of a thin shell (1-3 µm) of silica on an spherical inert core (e.g. glass). After 
the development of totally porous micro particulate packing, these have not been use in 
HPLC. 
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3. Totally porous silica particles (dia.<10 µm) 
These packing have widely been used for analytical HPLC in recent years. Particles of 
diameter >20 µm are usually dry packed, while particles of diameter <20 µm are slurry 
packed in which particles are suspended on a suitable solvent and the slurry so obtained 
is driven into the column under pressure. 
(d) Detectors 
A chromatography detector is a device used in high performance liquid 
chromatography (HPLC) to detect components of the mixture being eluted off the 
chromatographic column. The detector senses the presence of the individual 
components as they leave (elute) the column. The detector converts a change into an 
electric signal that is recorded by data system. 
CLASSIFICATION OF HPLC DETECTORS 
 UV/VIS  
   Fixed wavelength 
   Variable wavelength 
     Diode array (PDA) 
 Refractive index 
     Deflection detector 
     Refractive detector  
 Fluorescence detector 
 Electrochemical detector 
 Conductivity detector  
 Evaporative light scattering detector 
 Mass detector 
ULTAVIOLET/VISIBLE SPECTROSCOPIC DETECTORS 
 Measures the ability of solute to absorb light at particular wavelength(s) in the ultraviolet 
(uv) (or) visible (vis) wavelength range. When a light of a certain wavelength is directed at a 
flow cell, the substance inside the flow cell absorbs the light. As a result, the intensity of the 
light that leaves the flow cell is less than that of the light that enters it. An absorbance 
detector measures the extent to which the light intensity decreases (i.e. absorbance). 
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Fixed wavelength detector  
         Its absorbance of only one given wavelength is monitored by the system at all times 
(usually 254 nm) 
 Simplest and cheapest of the UV/VIS detector  
 Limited flexibility  
 Limited in types of compounds that can be monitored 
Variable wavelength detector 
 It a single wavelength detector is monitored at any given time, but any wavelength ina wide 
spectral range can be selected 
 Wavelength vary from 190-900 nm 
 More expensive, requires more advanced optics 
 More versatile, used for a wider range of compounds  
 More sensitive due to photomultiplier tube or amplification circuitry 
Photo Diode Array Detector 
Operates by simultaneously monitoring absorbance of solutes at several different 
wavelengths. Light from the broad emission source such as a deuterium lamp is collimated by 
an achromatic lens system so that the total light passes through detector cell onto a 
holographic grating. In this way, the sample is subjected to light of all wavelengths generated 
by lamp. The dispersed light from the grating is allowed to fall on to a diode array. The array 
may contain many hundreds of diodes and the output from each diode is regularly sampled by 
a computer and stored on hard disc. 
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VALIDATION  
According to ICH method validation is defined by establishing documented evidence which 
proves a high degree of assurance that a specific activity will consistently produce a desired 
result or product meeting its predetermined specification and quality characteristics.  
 
Validation parameters 
 Recovery 
 Response function 
 Sensitivity 
 Precision 
 Accuracy 
 Limit of detection 
 Limit of quantification 
 Robustness 
 Stability 
 System suitability 
 
 
 
(a) Recovery  
The absolute recovery of analytical method is measured as the response of a processed 
standard expressed as a percentage of response of pure standard which has not been subjected 
to sample pre-treatment and indicates whether the method provides a response for the entire 
amount of analyte that is present in the sample. It is performed by comparing the responses of 
extracted sample at low, medium and high concentration in replicates of at least 6 with those 
non-extracted standards which represent 100% recovery.   
 
𝑨𝒃𝒔𝒐𝒍𝒖𝒕𝒆 𝒓𝒆𝒄𝒐𝒗𝒆𝒓𝒚 =
𝑹𝒆𝒔𝒑𝒐𝒏𝒔𝒆 𝒐𝒇 𝒂𝒏𝒂𝒍𝒚𝒕𝒆
𝑹𝒆𝒔𝒑𝒐𝒏𝒔𝒆 𝒐𝒇 𝒂𝒏𝒂𝒍𝒚𝒕𝒆 𝒐𝒇 𝒑𝒖𝒓𝒆 𝒔𝒕𝒂𝒏𝒅𝒂𝒓𝒅
 
 
 (b)  Response function 
Peak area and peak height may be used as response function to define the linear 
relationship with concentration known as the calibration model. 
 
(c)   Sensitivity  
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 If small changes in the concentration method is said to be cause large changes in 
response function. The sensitivity of an analytical method is determined from the slope of the 
calibration line. The limit of quantification or working dynamic range of bio-analytical 
method is defined as the highest and lowest concentrations, which can be determined with 
acceptable accuracy.  According to this it will be set as ±15 for the upper and lower limit of 
quantification respectively. Any sample concentration that falls outside the calibration range 
cannot be interpreted from the calibration line and extrapolation of calibration curve is 
discouraged. If the concentration is over range, the sample should be diluted in drug-free 
matrix and re-assayed. 
(d)  Precision 
Precision is done to determine the valid estimation of a true value. It determines the 
variation in the result when the analytical process is repeated. Precision includes 
repeatability, intermediate precision and reproducibility. Precision and accuracy together 
determines the error of an individual determination. (Willard et.al 2015) 
Precision refers to the reproducibility of measurement with in a set that is the scatter of 
dispersion of a set about its central value. ‘Set’ means the number (n) of independent 
replication measurements of some property. Standard deviation is one of the most popular 
terms employed.   
(e)   Accuracy  
Accuracy refers to closeness of agreement with the true result. There are two methods for 
determining accuracy they are absolute method and comparative method. Accuracy is best 
reported as percentage bias. Accuracy is determined by replicate analysis of samples 
containing known amounts of analyte. The deviation of the mean from the true value serves 
as the measure of accuracy.  
1.  Calibration   
  When good calibration method is adopted then a good precision and 
accuracy can be obtained. The most convenient calibration function is linear, 
goes through the origin and is applicable over a wide dynamic range. Linearity 
identifies the range of concentrations over which the method response is 
proportional to the amount of analyte. In practise deviations may ocur from the 
ideal calibration curve. The major calibration equation used for analytical 
technique is  
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𝒚 = 𝒎𝒙 + 𝑪 
                                               m  = Slope 
                                               C = Intercept  
                  In calibration, univariate regression is applied, which means that all 
observations are dependent upon a single variable x. 
2. Standard deviation of slope 
The standard deviation of slope is proportional to standard error of estimate and 
inversely proportional to the range and square root of the number of data points. 
3. Correlation coefficient  
The correlation coefficient ‘r’ is more usefull to express the relationship of chosen 
scales. To obtain the correlation coefficient the co-variance is divided by the 
product of standard deviation of x and y.  
𝒓 =
𝟏
𝒏 − 𝟏
. ∑
𝒙𝒊 − ?̅?
𝒔𝒙
𝒏
𝒊=𝟏
.
𝒚𝒊 − ?̅?
𝒔𝒚
 
(f) Limit of detection (LOD) 
Limit of detection of an analytical method may be defined as the concentration which 
gives rise to an instrumental signal that is significantly different from the blank. They mainly 
depend upon the calibration curve for quantitative measurements, the IUPAC approach 
employs standard deviation of the intercept (Sa), which may be related to LOD and the slope 
of the calibration curve ‘b’ by 
𝑳𝑶𝑫 = 𝟑𝑺𝒂/𝒃 
(g) Limit of Quantification (LOQ 
Limit of quantification can be quantitative reliably with a specified level of accuracy and 
precision. LOQ represents the concentration of analyte that would yield a signal to noise ratio 
of 10. 
𝑳𝑶𝑸 = 𝟏𝟎𝑺𝒂/𝒃 
Sa = the estimate is the standard deviation of the peak area ratio of analyte to IS (5 
injection) of the drugs. 
b = slope of the corresponding calibration curve.  
(h) Robustness 
         According to ICH robustness is the” measure of its capacity to remain unaffected by 
small but deliberate variations in method parameters”. It   means the ability of the method to 
withstand the changes in method, reagents etc... The main parameters are pH of the mobile 
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phase, temperature, percentage of the organic solvent strength and buffer concentrations 
etc.to determine the robustness of the mehod experimental conditions were purposely altered 
and chromatographic characters were evaluated. 
(i) Stability  
The samples, standards and the reagents used for the HPLC method must be stable for a 
reasonable time ( e.g. one day ,one week, one month depending upon the need) for 
reproducible and reliable results. The analysis of even a single sample may require ten or 
more chromatographic runs to determine the system suitability, including standard 
concentrations to create a working analytical curve and duplicate or triplicate injections of the 
sample to be assayed. 
(j) System suitability 
All quality systems which are appropriate to analytical chemistry require that the 
equipment used is ‘fit for purpose’. It requires the performance characteristics of the 
measurement system meet the requirements of the analytical method. 
The system suitability tests includes  
I. Capacity factor(k) 
       It gives the fractional delay introduced by the separation process. This is equal to 
the ratio of the time spent by the analyte in the stationary and mobile phases. The 
capacity factor will be strongly affected by the solvent composition in HPLC.(Graham 
Currel) 
II.  Asymmetry 
The actual shape for a symmetrical peak can be represented by a Gaussian curve. 
The asymmetry of the peak can be defined by using the ratio between the forward and 
tailing half-widths of the peak. 
𝐴 10% = 𝑌/𝑋 
 
III. Separation factor 
      Separation factor is defined as the ratio between the capacity factors for the two 
components. The separation factor is a function of choice of stationary and mobile 
phase. It is denoted by α 
α=𝑘𝑎/𝑘𝑏 
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IV. Column efficiency 
      The efficiency of the column is the measure of its ability to produce a peak that is 
narrow in relation to its retention time. This is measured historically by the plate no 
(N).[ICH Q2B ,Q3B] .
[1-10] 
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LITERATURE REVIEW 
1. Kaushelendra mishra et al., (2011) developed and validated metformin hydrochloride 
in tablet dosage form. The analysis complied with beers law in the concentration 
range of 8-13 µg/ml at 233 nm for metformin. The validation of analytical method 
determination of metformin by UV in tablet formulation was performed in accordance 
the parameter including specificity, LOD, LOQ, Linearity and robustness. The 
linearity range between 8-13 µg/ml and correlation coefficient value was found to be 
0.9991.
[11]
 
2. A Madhukar et al., (2011) developed simple and sensitive method for metformin in 
RP-HPLC. Separation was achieved an inertsil - extend – C18 HPLC column (250 mm 
x 4.6 mm). 10 mM 1-octane sulfonic acid: Acetonitrile (80:20 v/v) as a mobile phase. 
The detection was carried out using PDA detector at 232 nm. The linear concentration 
range was 1-250 µg/ml and correlation co-efficient value was found to be 0.9995.
[12]
  
3. Dhaneswar et al., (2010) developed a method for metformin in bulk drug and 
formulation by HPTLC. Metformin was chromatographed on silica gel 60 F254 TLC 
plate using ammonium sulphate (0.5 %): 2-propanol: methanol (8: 1.6: 1.6 v/v/v) as 
mobile phase. Rf value was found to be 0.50 ± 0.03 it’s was scanned at 238 nm. The 
linear regression showed a good relationship with correlation co- efficient 0.999.
[13]
  
4.   K Heinig et al., (2004) developed fast liquid chromatographic – tandem mass 
spectrometric (LC-MS/MS) method for determination of metformin in plasma sample. 
This method employed a YMC cyano (2 mm x 50 mm , 3 µm) analytical column. For 
minimum sample preparation direct injection of samples after protein precipitation 
was performed. The polar column used with high organic mobile phase. A step 
gradient from 100 % ACN to ACN: Water (80:20 v/v) containing a 10 mM 
Ammonium acetate and 1% acetic acid. Second method a column switching LC-
MS/MS assay for online trapping was developed. Column used as YMC cyano 
column (250 mm x 10 mm, 5 µm) the mobile phase used as ACN:  Methanol (95 :5 
v/v). elution was performed isocrtically using 10mM ammonium acetate in ACN: 
Water (80:20 v/v) 1% formic acid. The linear range 10 – 10,000 ng/ml.[14] 
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5. H Amini et al., (2005) developed for the determination of antihyperglycemic agent 
metformin in human plasma using a novel sample extraction procedure. Liquid-liquid 
extraction of metformin and ranitidine (as internal standard) from plasma samples was 
performed with 1-butanol/n-hexane (50:50, v/v) in alkaline condition followed by 
back-extraction into diluted acetic acid. Chromatography was carried out using a 
silica column (250 mmx4.6 mm, 5 micron) under isocratic elution with acetonitrile-40 
mM aqueous sodium dihydrogen phosphate (25:75, v/v), pH 6. The limit of 
quantification (LOQ) was 15.6 ng/ml and the calibration curves were linear up to 
2000 ng/ml.
[15]
 
6. D R Brocks et al., (2010) developed a selective sensitive HPLC method for 
determination of metformin in human plasma and urine using conventional RP 
column and low specimen volume. Ranitidine is used as an internal standard and 
extraction was done form plasma and urine sample was performed with 1- butanol: 
hexane (50:50 v/v) mixture under alkaline conditions followed by back extraction into 
dil. acetic acid. Chromatography was carried out using C18 column (250 mm x 4.6 
mm, 5 µm). ACN: potassium dihydrogen orthophosphate (34:66 v/v) as mobile phase. 
The flow rate maintained at 0.7 ml/min. the linear regression range found to be 2-
2000 µg/ml. The mean absolute recoveries for 100 and 1000 ng /ml metformin 
hydrochloride in plasma using the present extraction procedure were 93.7 % and 88.5 
%, respectively.
[16]
 
7. Chandrabatla varaprasad et al., (2015) developed RP-HPLC method for the 
metformin and linagliptin using PDA detector at 225 nm. The linear range was 250 – 
2500 µg/ml and 1.25 – 12.5 µg/ml for metformin and linagliptin, respectively. 
Analytical column waters x-bridge C18 (500 mm x4.6 mm, 5 µ) was used at 
temperature of 30ºC ± 0.5ºC. CAN : 0.02 M phosphate buffer (PH-5) in the ratio of 35 
:65 v/v were used as mobile phase at a flow rate 1 ml/min. Retention time was 1.64 
and 4.6 min for metformin and linagliptin  respectively.
[17]
   
8. K Neelema et al., (2014) developed a gradient RP-HPLC method for metformin, 
voglibose and glimepiride in bulk and combined tablet dosage form. The separation 
carried out for three drug was based on the use of inertsil ODS 3V (150 mm x 4.6 
mm, 5 µm) column in a gradient mode. The mobile phase was consisting of 0.02 m 
phosphate buffer (PH- 2.5) adjusting with Orthophosphoric acid (solution A) and 
acetonitrile (solution B). The flow rate was 1ml/min and detection at 230 nm. The 
retention time 2.423, 8.19 and 11.708 of metformin, voglibose and glimepride, 
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respectively. The linear for metformin, voglibose and glimepride at concentration 
range of 200-600 µg/ml, 0.08-0.24 µg/ml and 0.8-2.4 µg/ml.
[18]
 
9. A R Shirode et al., (2014) developed RP-HPLC and HPTLC methods for 
simultaneous estimation of metformin hydrochloride and vidagliptin from bulk and 
marketed formulation. The separation was carried out by HiQsil C18 HS (250 mm 
x4.6 mm) column and detection was carried out by using variable wavelength 
detector. Phosphate buffer: methanol: Acetonitrile (50:30:20 v/v/v) used as mobile 
phase and flow rate was 0.8 ml/min. metformin and vidagliptin were retention time 
3.7 min and 4.8 min, respectively. Linear range was 10-60 µg/ml for metformin and 
vidagliptin, respectively.
[19]
 
10. G Saravanakumar et al., (2014) developed and validated consistent UPLC method for 
metformin, pioglitazone and glimepride in tablet dosage form. UPLC separation was 
achieved on symmetry C18 (2.1mm x 100 mm, 1.7 µm) as isocratic mode. Phosphate 
buffer: methanol (UPLC grade) was used as mobile phase. The flow rate was 0.25 
ml/min. The retention time was 0.002 min, 1.77 min and 2.409 min for metformin, 
pioglitazone and glimepride, respectively. Linearity range was 400-600 ppm for 
metformin, 12-18 ppm for pioglitazone and 0.8-1.2 ppm for glimepride. The % 
recovery was found to be 99.7%-100.9%, 98.4%-100.9% and 99.9%-101.2% for 
metformin, pioglitazone and glimepiride, respectively.
[20]
  
11. F AI- Rimawi (2009), developed and validated an analytical method for metformin 
and its related compound (1-cyanoguanidine) in tablet formulation by HPLC-UV. 
Liquid chromatography with UV- detector at a wavelength 232 nm using novapak 
silica column an isocratic elution was employed using a mixture of ammonium 
dihydrogen phosphate buffer and methanol (21:79 v/v). The linearity range was 0.01-
0.03 mg/ml of metformin. The accuracy was found to be 100.4%.
[21]
  
12. P Madhusudhan et al., (2015) developed and validated RP-HPLC method for 
simultaneous estimation of metformin and rosiglitazone in bulk and tablet dosage 
form. Isocratic chromatography was performed on a symmetry column (150mm x 4.6 
mm, 5 µm, xTeera) with the mobile phase consisting of 70:30 % v/v (methanol: 
phosphate buffer) with the flow rate of 0.5 ml/min  and detection at239 nm. The 
retention time for metformin and rosiglitazone was found to be 3.33 and 5.69 min 
respectively.
[22]
  
13. Ashutosh et al., (2015) developed and validated a stability indicating RP-HPLC 
method for simultaneous estimation of metformin and alogliptin in human plasma. 
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The drug was spiked in plasma and extracted by precipitation method. The extracted 
analyte was injected into xTeera column C18 (150 mm x 4.6 mm, 3.5 µm) temperature 
maintained at 25˚ C and effluent monitored at 235 nm. The mobile phase was sodium 
dihydrogen orthophosphate: ACN (70:30 v/v). The flow rate was maintained 1ml/min. 
The linear range from 300-700 µg/ml for metformin and 7.5-17.5 µg/ml for alogliptin, 
respectively.
[23]
 
14. Chirag et al., (2014) developed and validated UV spectrophotometric method for 
simultaneous estimation of metformin and alogliptin in bulk drugs and combined 
dosage form. Method A is simultaneous equation which is based on measurement of 
absorption at 277 nm and 232 nm. i.e, λ max of alogliptin and metformin respectively. 
Method B is Q absorbance ratio method which based on measurement of absorption at 
wavelength at 250 nm and 277 nm. i.e, iso-bestic point of alogliptin and metformin 
respectively. Linearity range of alogliptin 5-25 µg/ml and 1-10 µg/ml of metformin. 
The accuracy found within a range of 95-102 %.
[24]
 
15. Dyade et al., (2013) developed and validated uv visible spectrophotometric method 
for metformin and glimepiride. The dosage form contains 2 mg of glimepiride and 
500 mg of metformin and the ratio of both drugs in the dosage form 1:250. Metformin 
freely soluble in water whereas glimepiride practically insoluble in water so first both 
the drugs are separated by solvent extraction method and individually determine by 
UV absorbance method. The linear range of metformin 8-40 µg/ml ad 5-30 µg/ml of 
glimepiride.
[25]
 
16. Laxmi gowsami et al., (2010) developed simultaneous estimation of metformin and 
pioglitazone by ultraviolet spectrophotometry. This method deals with the bilayer 
tablet dosage form without prior separation techniques. The methods employed are 
derivative spectrophotometric method and Q analysis. In the quantitative assay of two 
components by Q-analysis method, absorbances were measured at two wavelengths, 
one being iso-bestic point and other being the wavelength of maximum absorption of 
one of the two components. 247.5 nm was the iso-bestic point of both drugs and 231 
nm was λmax of metformin. The linearity range of pioglitazone 0.5-4.5 µg/ml of 
pioglitazone and 16.5-150 µg/ml of metformin, respectively.
[26]
 
17. B Amruta et al., (2012) developed and validated a simultaneous estimation of 
metformin and sitagliptin phosphate by UV. Two methods are developed method A is 
absorbance ratio method which is based on measurement absorption at maximum 
wavelength 266 nm and 232 nm for sitagliptin and metformin, respectively. Method B 
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area under curve in the wavelength range of 244 - 279 nm for sitagliptin and 222 - 
240 nm for metformin, respectively. Linearity range was 25-225 µg/ml of sitagliptin 
and 2 - 12 µg/ml for metformin. The accuracy was found to be 99.64 and 98.9 % for 
sitagliptin and metformin, respectively.
[27]
 
18. R Sejal et al., (2012) developed and validated an analytical method for quantitative 
estimation of miglitol and metformin in combined dosage form. The developed 
method employs multicomponent spectroscopy using 300nm, 270 nm, 240 nm and 
210 nm as wavelength for estimation. Miglitol and metformin were found to be linear 
in the concentration range of 0.2-1.2 µg/ml and 2-12 µg/ml, respectively. The 
accuracy was found to be within a range of 99.27 – 99.92 % and 99.29 – 99.97 % of 
metformin and miglitol, respectively.
[28]
  
19. P Kabra et al., (2011) developed a simultaneous estimation of Voglibose and 
Metformin by UV. The developed method employs multicomponent spectroscopic 
method using 325 nm, 285 nm, 245 nm and 205 nm. Voglibose was found to be 
absorbing prominently at 190 nm with smaller peak in the range of 325 nm to 245 nm 
while metformin absorbed at 232 nm. The content of analyte formulation was found 
to be 98-100.12%.
[29]
 
20. K Darshana et al., (2013) developed HPTLC method for simultaneous determination 
of Metformin and Sitagliptin in tablet dosage form. Chromatographic separation was 
performed on silica gel 60 F254 plates with buffer: water: glacial acetic acid (6:2:2 
v/v/v) as mobile phase. The Rf value was 0.35 ± 0.01 for Metformin and 0.75 ± 0.01 
for Sitagliptin. Detection was carried out at 227 nm.
[30]
 
21. R Dhaneswar et al., (2010) developed and validated HPTLC method for simultaneous 
estimation of Metformin, Atorvastatin and Glimepiride in bulk drugs and formulation. 
Chromatographic separation of the drug was performed on aluminum plates precoated 
with silica gel 60F254 as the stationary phase and the solvent system water: methanol: 
ammonium sulphate (1:1:4 v/v/v). Densitometric quantification at 237 nm. The Rf 
value was 0.37 ± 0.02, 0.59± 0.02, 0.75 ± 0.02 for Metformin, Atorvastatin and 
Glimepiride respectively. The linearity range was 200-700 ng/spot for Metformin, 
600-2100 ng/spot for Atorvastatin and 600-2100 ng/spot for Glimepiride.
[31]
 
22. Thomas et al., (2011) developed a stability indicating HPTLC method for 
simultaneous estimation of nateglinide and metformin in pharmaceutical dosage form. 
Study was performed on pre-coated silica gel 60 F254 using chloroform: ethyl acetate: 
acetic acid (14:6:0.1 v/v/v) as a mobile phase. A TLC scanner set at 216 nm. The 
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correlation coefficients of calibration curve were found to be 0.996 and 0.995 in the 
concentration range of 200 – 2400 and 500 – 3000 ng/band for Nateglinide and 
Metformin, respectively.
[32]
 
23.  Veeresham et al., (2010) developed and validated stability indicating HPTLC method 
for simultaneous estimation of Linagliptin and Metformin. Chromatographic 
separation was carried out a silica gel 60 F254 with acetone: methanol: chloroform: 
formic acid (3:1:5:1 v/v/v/v) as mobile phase followed by densitometrically analysed 
at 230 nm. The Rf value was 0.72 and 0.19 for Linagliptin and Metformin, 
respectively.
[33]
  
24. Eman I.EI- kimary et al., (2015) developed and validated HPTLC determination of 
three gliptins in binary mixtures with Metformin. The method was developed for the 
determination of Linagliptin, Saxagliptin (or) Vidagliptin in their mixture with 
metformin in pharmaceutical preparation using preferable green mobile phase system. 
Separation was carried out on Merck HPTLC silica gel 60 F254 plates using methanol: 
0.5% ammonium sulphate (18:2 v/v) as mobile phase. Densitometrically analysed at 
225 nm for Linagliptin, mixtures and 208 nm for both Saxagliptin and Vidagliptin 
mixtures. The linear regression range was 0.05-0.5 µg/band for Linagliptin and 0.2-2 
µg/band for Saxagliptin and 5-40 µh/band for Vidagliptin.
[34]
   
25. Vinyas et al., (2016) developed and validated a RP-HPLC method for alogliptin. In 
this method ACN: phosphate buffer used as a mobile phase with the flow rate of 1 
ml/min. the optimizing wavelength detection at 254 nm. The column used as Shisedio 
C18 (250mm x 4.6 mm, 5 µm). The linearity was observed in the range of 10-35 µg/ml 
and correlation co-efficient were 0.991.
[35]
 
26. Komal Sharma et al., (2015) developed and validated HPTLC method for estimation 
of Alogliptin in bulk drugs and tablet dosage form. Chromatographic separation was 
carried out on Merck HPLTLC aluminium sheets of silica gel 60 F254 using 
acetonitrile: 1% ammonium acetate in methanol (4.5:5.5 v/v) as mobile phase 
followed by densitometry analysis at 277nm. The reliability of the method was 
assessed by evaluation of linearity (500-5000 ng/spot) for Alogliptin. The accuracy of 
the method was found to be in the range of 98-102 %. Due to non-availability of the 
product, 400 mg tablets were punched containing 34 mg of Alogliptin.
[36]
 
27. Supriya et al., (2016) developed and validated UV spectrophotometric and RP-HPLC- 
PDA methods for the estimation of Alogliptin. UV spectrophotometric method was 
performed using UV/Vis double beam spectrophotometer with a spectral bandwidth 
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of 1nm and 1 cm matched quartz cells. The maximum absorbance of Alogliptin was 
observed at 276 nm using methanol as a solvent. RP-HPLC method was carried out 
on a Unisol RP C18 column (150 mm x 4.6 mm, 4.6 µm) with a mobile phase 
composed of methanol and 10 mM ammonium acetate in the ratio of 80:20 v/v with a 
flow rate of 0.8 ml/min. The linearity of the method was found to be in the range of 5-
35 µg/ml (uv) and 20-100 µg/ml (RP-HPLC) and the correlation values was 0.999 for 
both the methods.
[37]
 
28. Sunilkumar et al., (2016) developed a visible spectrophotometric method for 
quantification of alogliptin using utility of picric acid and 2, 4 dinitrophenol as 
chromogenic reagent. Two simple and sensitive visible spectrometric method (A & B) 
were developed for the estimation of alogliptin in bulk and its tablet dosage form. The 
methods use the reaction of alogliptin with picric acid (method A) or 2, 4 
dinitrophenol (method B) in the chloroform medium. The complex alogliptin with 
picric acid (method A) or 2, 4 dinitrophenol (method B) showed λmax at 415 nm and 
430 nm respectively. The different conditions affecting the formation and stability of 
the complexes were optimized. The methods were validated statistically according to 
ICH. The calibration curve is linear in the range of 10-60µg/ml and 10-50µg/ml for 
methods A and methods B, respectively.
[38]
 
29. Venugopala rao et al., (2014) developed and validated a chiral HPLC method for the 
enantiomeric purity of alogliptin benzoate. An isocratic chiral stationary phase was 
used for the quantitation of (S) - isomer in alogliptin. Separation was achieved with a 
Lux cellulose 3 (250 x 4.6 mm, 5 µm) column. The ratios of ethanol and diethyl 
amine in the mobile phase were optimized to obtain the best separation. UV detection 
was performed at 230 nm. The described method is linear over a range of LOQ – 
1.5µg/ml of (S)- isomer.
[39]
  
30. Ida Fejos et al., (2014) developed a separation of alogliptin enantiomers in 
cyclodextrin modified capillary electrophoresis. Preliminary screening of the native 
CDs and their ten derivatives revealed that sulfopropylated-γ-CD, sulfopropylated-β-
CD and sulfopropylated-γ-CD, sulfobutyl-ether-β-CD (SBE-β-CD) and sulfobutyl-
ether-γ-CD enabled enantioresolution. Furthermore, cavity size dependent enantiomer 
migration order reversal was observed between γ- and β-CD derivatives. To improve 
enantioseparation, buffer composition and pH, CD concentration, applied voltage, 
temperature, and injection parameters were optimized for the Alo/ SBE-β-CD system, 
yielding a resolution of 8.34. RSD percentage of the resolution value, migration times, 
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and corrected peak areas were below 3 and 5% during testing repeatability and 
intermediate precision. LOD and LOQ values were found to be 2 and 6 μg/mL, 
respectively, for each enantiomer. Calibration lines ranging from 6 to 250 μg/mL 
were constructed with r
2
 > 0.9997. Robustness could be successfully verified by using 
the Plackett–Burman statistical experimental design. The optimized system containing 
5 mM SBE-β-CD in a 25 mM acetate buffer at pH 4.75 was found promising to detect 
0.1% distomer in the presence of the API.
[40]
 
31. I Ramzia et al., (2012) developed a liquid chromatographic determination of 
alogliptin in bulk and pharmaceutical preparation. This method developed based on 
isocratic elution using a mobile phase containing potassium dihydrogen 
orthophosphate buffer: acetonitrile (20:80 v/v) at a flow rate of 1 ml/min with UV 
detection at 215 nm. Chromatographic separation was achieved on a symmetry 
cyanide column (150 mm x 4.6 mm, 5µm). Linearity, accuracy and precision were 
found to be acceptable range of 5-160 µg/ml for alogliptin in bulk.
[41]
   
32. M Anusha et al., (2014) develop and validate RP-HPLC method for Pioglitazone and 
alogliptin in combined tablet dosage form. Determination of alogliptin and 
Pioglitazone using mobile phase (mixture phosphate buffer and acetonitrile in the 
ratio of 35:65) as the solvent. The proposed method involves the measurement of 
retention time at selected wavelength. 268 nm was selected as the analytical 
wavelength. The retention time of alogliptin and Pioglitazone was found to be 3.113 
and 5.234 respectively. The linearity of the proposed method was investigated in the 
range of 2.5-15 µg/ml. for alogliptin and 3-18 µg/ml for Pioglitazone respectively.
[42]
 
33. Komal Sharma et al., (2015) developed and validated HPTLC method for 
simultaneous determination of alogliptin and Pioglitazone in bulk drugs and combined 
dosage form. Chromatographic separation was carried out using Merck HPTLC silica 
gel 60 F254 plates using acetonitrile: 1% ammonium acetate in methanol (4.5:5.5 v/v) 
as mobile phase followed by densitometry analysis at 254 nm. The reliability of the 
method was assessed by evaluation of linearity (500-3000 ng/spot for alogliptin as 
well as Pioglitazone).The accuracy of the method was found to be within a range of 
98-102%.
[43]
 
34. Anees et al., (2015) developed a simultaneous estimation of alogliptin and metformin 
from its tablet dosage form by area under curve and multicomponent uv 
spectrophotometric method. Two simple, accurate and precise UV methods were 
developed for the estimation of alogliptin and metformin in tablet dosage form. 
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Method A is area under curve spectrophotometry and in this the wavelength range 
selected for quantitation are 215- 240 nm for alogliptin and 265-293 nm for 
metformin. Method B is multicomponent mode wavelength selected for quantitation 
method were metformin and alogliptin therefore for 284nm (λ max of metformin) and 
274 (λ max of alogliptin) for the analysis. In both the methods linearity for detector 
response was observed in the concentration range of 10-50 µg/ml for MET and ALO 
respectively. The results of tablet analysis for area under curve was found to be 99.90 
±0.151 for ALO and 99.62 ±0.220 for MET and result obtained for multicomponent 
was 99.73 ± 0.306 for ALO and 99.30 ±0.224 for MET.
[44]
 
35. Dimal et al.,(2017) developed a estimation of Pioglitazone Hydrochloride and 
Alogliptin Benzoate in Combination by Second Order Derivative Spectrophotometry 
method. A simple and accurate method for analysis of Pioglitazone hydrochloride and 
alogliptin benzoate in their combination was developed using second order derivative 
spectrophotometry. Pioglitazone and alogliptin were quantified using second order 
derivative responses at 267 nm and 278 nm prepared in methanol. The calibration 
curves were found to be linear in the concentration range of 10-30 µg/ml for both 
Pioglitazone and alogliptin.
[45]
  
36. K Swathi et al., (2015) developed the simultaneous estimation of metformin and 
alogliptin by using RP-HPLC. Chromatographic separations were done by using the 
column X Bridge RP C18 (4.6 mm x 50 mm). Methanol: Acetonitrile: Phosphate buffer 
(pH 7) in the ratio of 40:20:40. The flow rate was maintained at 1 ml/min. both the 
drugs are dissolved in the mobile phase. The UV spectrum was taken for selection of 
wavelength. The isobestic point was taken as detection wavelength. The linearity 
study of metformin and alogliptin was found in the concentration range of 50 µg to 
250 µg and 5µg to 25 µg.
[46]
 
37. S.Mowaka et al., (2017) developed a comparative study between UHPLC-UV and 
UPLC-MS/MS methods for determination of alogliptin and metformin in their 
pharmaceutical combination. Concerning method A, separation was achieved by 
Hypersil gold (50mm x2.1 mm, 1.9 µm) column, using acetonitrile and 0.2%formic 
acid aqueous solution as the mobile phase with a gradient elution. Electrospray 
ionization source was operated in a positive ion mode. Selected reaction monitoring 
mode on a triple quadropole mass spectrometer was used do quantify the drugs 
utilizing the transitions of 340.33- 116.32 (m/z) and 130.12- 71.32 (m/z) for alogliptin 
and metformin, respectively. Concerning method B, it was achieved on a Symmetry 
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C18 column (100mm x 2.1 mm, 2.2 µm) applying an isocratic elution based on 
methanol: water in the ratio of (10:90 v/v) at pH 3 as mobile phase. The photodiode 
array detector was operated at 210 nm. Method A showed the good linearity over the 
concentration range of 5-400 ng/ml and 20-2000 ng/ml for alogliptin and metformin, 
respectively, while method B showed satisfactory results using ranges of 0.25-8 µg/ml 
and 5-50µg/ml for alogliptin and metformin, respectively.
[47]
 
38. G Hemavathi et al., (2017) developed a sensitive LC-MS/MS method for 
simultaneous determination of alogliptin and voglibose in human plasma. A highly 
sophisticated and sensitive LC-MS/MS method has been developed and validated for 
the alogliptin and voglibose simultaneous determination in human plasma. Alogliptin 
D3 and miglitol were used as IS. Chromatography conditions included an isocratic 
mobile phase consisting of 5 mM ammonium formate: acetonitrile in the ratio of 
20:50 v/v. the column used was Welchrom XB C18, with specification of 50 x 4.6 
mm, 5µm, at a flow rate of 0.70 ml/min. The retention time of alogliptin, voglibose, 
alogliptin D3 and miglitol occurred at 1.03, 0.8, 0.8 and 0.81 min respectively and the 
total chromatographic run time was 3.0 min. Alogliptin and voglibose achieved a 
linear regression in human plasma at 5.09-509 ng/ml and 2.03-203 ng/ml 
respectively.
[48]
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AIM AND PLAN OF WORK 
AIM 
Analytical methods are intended to establish the identity, purity, physical characteristics and 
potency of the drugs. Methods may also support safety and characterization studies or 
evaluation of drug performance. 
From the viewpoints mentioned above, the present work was undertaken to develop and 
validate an analytical methods for the estimation of metformin and alogliptin in 
pharmaceutical dosage form and from plasma. 
 
PLAN OF WORK 
Literature survey revealed that analytical methods have been reported for the estimation of 
the metformin and alogliptin individually and in combination with other drugs. Hence, the 
present work aims to develop and validate a spectroscopic and chromatographic method for 
estimation of the metformin and alogliptin from pharmaceutical dosage form and from 
plasma in the following stages; 
 Selection, optimization of chromatographic parameters 
 Validation of proposed methods 
 Application of proposed methods to formulation   
 
 
 
.   
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                                                            DRUG PROFILE 
 METFORMIN 
 
     Chemical structure                     : 
 
 
Molecular weight  :  129.16364 g/mol 
IUPAC name    :  3-(diaminomethylidene)-1,1-dimethylguanidine 
Empirical formula  :  C4H11N5 
Pharmacopeial status  :  official in IP,BP, USP 
Description  :  white crystalline powder 
Solubility  : Freely soluble in water and practically insoluble in 
acetone, ether and chloroform. 
Contra indications                        :  kidney disorders, lung diseases, liver diseases. 
Pharmacological action 
Oral hypoglycemic agent. It is used in the first line therapy in the treatment of type –ii 
diabetes mellitus. It decreases blood glucose levels by decreasing hepatic glucose 
production and improving insulin sensitivity by increasing peripheral glucose uptake and 
utilization. 
    Adverse drug reaction     : gastrointestinal irritation including diarrhoea, nausea,    
vomiting. 
Storage      : store at room temperature 
[49] 
 
 
 
 
 
 
Drug profile 
 
Department of pharmaceutical analysis 39 
 
ALOGLIPTIN
 
 
Chemical structure                      : 
 
 
 
Molecular weight :     339.39 g/mol 
IUPAC name  : 2-({6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-            
dioxo-3, 4-dihydropyrimidin-ethyl) benzonitrile 
Empirical formula :     C18H21N5O2 
Pharmacopeial status :     official in USP 
Description  :     colourless fine powder 
Solubility :    soluble in methanol, sparingly soluble in water 
  Indications                                    : Indicated as an adjunct diet and exercise to improve     
glycemic control in adults with type 2 diabetes mellitus. 
Pharmacological action     
Novel hypoglycemic drug belongs to dipeptidyl peptidase-4 inhibitor group, which 
normally degrades the incretins glucose dependant insulin tropic polypeptide (git) and 
glucagon like peptide. 
Adverse drug reaction             :  hypoglycaemia, joint pain.  
Storage        :  store in cool temperature. 
 
Presentation      :   film coated tablet. 
Trade name                                      :   Kazano [Metformin 500mg, Alogliptin 12.5mg] 
[50, 51] 
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MATERIALS AND INSTRUMENTS 
Drug sample 
 Metformin HCl was received from Cadila pharmaceutical, Ahmedabad, Gujarat. 
 Alogliptin was kindly supplied by Vivan Life sciences, Thane, Maharashtra. 
  The formulation KAZANO® (Metformin and Alogliptin) 500-12.5mg tablets 
(Takeda, Canada) were purchased from Pharmasave pharmacy, Canada. 
 Chemicals and solvents used  
 Methanol HPLC grade - Himedia laboratory Pvt Ltd, Mumbai. 
 Water for HPLC – RFCL Ltd, Delhi. 
 Acetonitrile HPLC grade Sigma-Aldrich chemicals Pvt Ltd, Bangalore. 
 Ammonium solution 30% Loba chem., Mumbai. 
 Potassium dihydrogen orthophosphate Himedia laboratory Pvt Ltd, Mumbai. 
 Ammonium sulphate (0.5 % v/v) – Hi-pure fine chem industries, Chennai. 
 Chloroform – Avantor performance materials India Ltd, Maharashtra.  
Instruments used ` 
HPLC System Shimadzu 
HPLC Software  Lab solution 
Pump Shimadzu LC-10ATVP 
Photodiode array detector  Shimadzu  (SPD- M10AVP) 
Column Phenomenex C18 (250x4.6mm ID, 5µm) 
UV double beam spectrophotometer UV- 1650 PC Shimadzu, Japan  
HPTLC system  CAMAG (winCATS) 
pH meter LABINDIA, New Delhi  
Sonicator Ultrasonic 
Centrifuge  Eppendrof 5415 
Analytical balance AND HR-200 
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DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS ESTIMATION OF 
ALOGLIPTIN AND METFORMIN IN COMBINED DOSAGE FORM BY UV 
METHOD 
 
SELECTION OF SOLVENT 
Solution of metformin hydrochloride (40 µg/ml) and alogliptin (1 µg/ml) were prepared in 
Methanol, 0.05N Sodium hydroxide and Acetonitrile. UV spectrum of the solution recorded 
and overlain spectra of metformin and alogliptin in the solutions shown in the Fig.1 to 3. 
 SELECTION OF WAVELENGTH 
Absorbances of both the drugs were higher and gave good sharp peak in methanol, so it was 
decided to prepare drug solution in methanol for further studies. The λ max of metformin and 
alogliptin were found to be 237 nm and 225 nm respectively.   
ANALYSIS OF FORMULATION 
PREPARATION OF STANDARD SOLUTION  
Stock solutions of metformin (400 µg/ml) and alogliptin (10 µg/ml) are prepared in methanol. 
A solution of metformin (40 µg/ml) and alogliptin (1 µg/ml) and mixture of metformin and 
alogliptin (40 µg/ml and 1 µg/ml) were prepared in methanol. The solutions were scan in UV 
region and the overlain spectra as shown in Fig. 4. From overlain spectra, wavelength 237nm 
and 225nm were selected. The different concentration of metformin (2 µg/ml to 10 µg/ml) 
and alogliptin (0.05 µg/ml to 0.25µg/ml) and mixture of metformin and alogliptin (2.05 
µg/ml to10.25 µg/ml) were prepared from respective stock solution and scan in UV region 
and spectrum shown in Fig 5, 6. 
The absorbances were noted at selected wavelengths, Table 1 and 2.  
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PREPARATION OF SAMPLE SOLUTION 
20 tablets each containing 500 mg of metformin and 12.5 mg of alogliptin were weighed and 
quantity equivalent to 40 mg of metformin and 1 mg of alogliptin were dissolved in 
Methanol. Sonicated for 20 mins and make upto the mark by using same. The solution was 
filtered and further diluted to get a concentration 40 µg/ml and 1 µg/ml of metformin and 
alogliptin respectively. The UV spectrum shown in Fig. 11. 
Absorbances were noted at 237 nm and 225 nm and amount of metformin and alogliptin were 
calculated using simultaneous equation method, formula is given below.  
   
And 
   
 
Where,  
 A1 and A2 are absorbances of formulation at 237 and 225 respectively, 
 Cx and Cy are the concentration of metformin and alogliptin respectively, 
           ax1 and ax2are absorptivities of metformin at 237 and 225 respectively, 
 ay1 and ay2 are absorptivities of alogliptin at 237 and 225 respectively, 
 % Label claim and estimated amount had shown in Table No 3. 
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VALIDATION 
LINEARITY: 
1. Metformin 
Metformin was found to be linear at the concentration range of 2-10 µg/ml.  The 
absorbance of this solution was noted at the wavelength 237nm and 225nm and 
calibration curve were plotted using concentration Vs absorbance. Fig.7and  8.  
At wavelength 237 nm- slope, intercept and correlation coefficient values were 
found to be 0.10125, 0.01810 and 0.99936. 
At wavelength 225 nm- slope, intercept and correlation coefficient values were 
found to be 0.0630, 0.05180 and 0.99963. 
2. Alogliptin  
     Alogliptin was found to be linear at the concentration range of 0.05-0.25 
µg/ml.  The absorbance of this solution was noted at the wavelength 237nm and 
225 nm and calibration curve were plotted using concentration Vs absorbance. 
Fig. 9 and 10. 
At wavelength 237 nm- slope, intercept and correlation coefficient values were 
found to be 0.13000, 0.00030 and 0.933. 
At wavelength 225 nm- slope, intercept and correlation coefficient values were 
found to be 0.10000, 0.0232 and 0.9968. 
ACCURACY 
To study the reliability, suitability and accuracy of the method recovery experiments were 
carried out.  To the formulation equivalent to 40 mg of metformin and 1 mg of alogliptin at 
the level of 80 % and 100 % pure metformin and alogliptin were added and suitably diluted. 
The contents were determined from respective chromatogram and table shown in Table 4. 
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PRECISION 
Precision of the method was demonstrated by, 
 Intraday precision 
 Interday precision 
1. Intraday precision 
 Intraday precision was found out by carrying out analysis of standard drug 
solution at three different concentrations in the linearity range for three times on 
the same day and %RSD was calculated. 
2. Interday precision 
Interday precision was found out by carrying out analysis of standard drug 
solution at three different concentrations in the linearity range for three day over a 
period of one week and %RSD was calculated. 
STABILITY 
The sample solution was subjected to stability studies under room condition. Stability was 
studied looking for any change in absorbance and peak shape when compared to UV spectra 
of freshly prepared solution. The solution store under room temperature was stable upto 3 
hours. 
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OVERLAIN SPECTRA OF METFORMIN AND ALOGLIPTIN IN VARIOUS 
SOLVENTS 
 Fig.1. Overlain spectra in Methanol 
 
Fig. 2. Overlain spectra in 0.05N sodium hydroxide 
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Fig.3. Overlain spectra in Acetonitrile  
 
Fig. 4. Overlain spectra of Metformin, Alogliptin and Mixture 
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Fig. 5. Overlain spectra of Metformin (2-10 µg/ml) 
 
Fig. 6. Overlain spectra of Alogliptin (0.05-0.25 µg/ml) 
 
 
Experimental section 
 
Department of pharmaceutical analysis 48 
 
 
Table No.1 Absorbance of metformin at selected wavelength. 
S. No Concentration (µg/ml) Absorbance at 237nm Absorbance at 225nm 
1 2 0.217 0.181 
2 4 0.420 0.298 
3 6 0.640 0.433 
4 8 0.823 0.554 
5 10 1.028 0.683 
 
Table No.2 Absorbance   of alogliptin at selected wavelength. 
S. No Concentration (µg/ml) Absorbance at 237nm Absorbance at 225nm 
1 0.05 0.009 0.028 
2 0.1 0.010 0.033 
3 0.15 0.019 0.039 
4 0.2 0.023 0.043 
5 0.25 0.035 0.048 
 
Fig.7. Calibration graph of Metformin at 237nm 
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Fig.8. Calibration graph of Metformin at 225nm 
 
Fig.9. Calibration graph of Alogliptin at 237nm 
  
Fig.10. Calibration graph of Alogliptin at 225nm
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Table No.3 Analysis of formulation 
S.No Drug Amount(mg) %Label claim %RSD* 
Labeled Found 
1 MET 500 498 99.6 0.32 
2 ALO 12.5 12 96 0.85 
*RSD of five observations 
Table No.4 Recovery studies 
S.No Level %Recovery %RSD* 
MET ALO MET ALO 
1 80% 99.82 98.60 0.201 0.260 
2 120% 98.80 101.50 0.106 0.424 
*RSD of five observations 
Fig.11. Spectra of formulation  
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DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR 
SIMULTANEOUS DETERMINATION OF ALOGLIPTIN AND METFORMIN IN 
FIXED DOSE COMBINATION TABLET 
 
SELECTION OF SOLVENT  
Ideal properties of solvents are listed below: 
 Drug should be freely soluble in the solvent used 
 Drug should show stability in solvents used  
 Solvent should be volatile  
Accordingly methanol was selected as solvent for further studies. 
 SELECTION OF WAVELENGTH 
The maximum wavelength absorption of drug at 254 nm which was selected as the detection 
wavelength. 
SELECTION OF STATIONARY PHASE 
Different plates are available with the different size, which should be selected based on the 
analyzing compound. HPTLC Silica gel 60 F254 HPTLC (10*10 or 10*20) plates are used as a 
stationary phase for the studies. 
MOBILE PHASE SELECTION AND OPTIMIZATION 
Mobile phase for HPTLC method is selected and optimized on the basis of analyst’s own 
experience, literature report of similar studies and traditional trial and error method. A 
solvent system that would give dense compact spots and good separation from the application 
position and solvent front was to be selected. 
 Initially different solvent systems like 
1. Chloroform : Methanol (4:6) 
2. Ethyl acetate : Formic acid : Chloroform (2:3:5) 
3. Chloroform : Methanol  : Ammonia (5:3:2)    
4. n - butanol : Ethanol : Ammonia (4:4:2) 
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5. Acetone : Methanol : Toluene : Formic acid (4:3:2:1) 
6. Acetonitrile : Chloroform (4:6) 
7. Methanol : Ammonia : Acetone : Formic acid (3:2:4:1) 
8. Chloroform : Ammonia : Acetone : Formic acid (3:2:4:1) 
9. Methanol : Ammonium sulphate (0.5%) : Propanol : Ammonia (3:4:2:1)  
10. Acetonitrile : Methanol : Ammonium acetate (1%) : Ammonium sulphate (0.5%) 
(3:3:2:2) 
11. Chloroform : Methanol : 0.5% Ammonium sulphate (4:4:2) 
Among these systems, Chloroform: Methanol: 0.5% Ammonium sulphate (4:4:2) was 
selected because in this system good compact and dense spots were obtained. 
 Separation using Chloroform: Methanol: 0.5 % Ammonium sulphate  
Different ratios of the Chloroform: Methanol: 0.5 % Ammonium sulphate as tried and from a 
ratio of (4:4:2 v/v/v) was selected because it gave good separation from the application 
position and solvent front. 
   FIXED EXPERIMENTAL CONDITION 
             Stationary phase               :   pre – coated silica gel 60 F254 on aluminium sheets 
  Mobile phase                    :   Chloroform: Methanol: Ammonium sulphate (0.5%)  
                                                             (4:4:2) 
  Chamber saturation           :   20 min 
  Migration distance            :    7 cm 
  Band width                        :    8mm 
  Slit dimension                   :    6 x 0.3 mm 
  Source of radiation            :   Deuterium lamp 
  Wavelength of scanning    :   254 nm 
              Rf values 
        Metformin                     :    0.44 ± 0.02 
        Alogliptin                      :    0.66 ± 0.02 
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ANALYSIS OF FORMULATION  
PREPARATION OF STANDARD SOLUTION  
Accurately weighed 10 mg quantity of Alogliptin and 400 mg of Metformin were taken and 
transferred into a 10 ml clean volumetric flask. The drugs were dissolved in methanol and 
made up to the volume methanol to obtain 1000 µg/ml of Alogliptin and 40000 µg/ml of 
Metformin (stock solutions). Aliquots of standard solutions were applied in the concentration 
range of 100-500 ng/spot of Alogliptin and 4000-20000 ng/spot of Metformin by applying 
0.1 -0.5 µl prepared standard solutions, which were used for calibration purpose. 
PREPARATION OF SAMPLE SOLUTION 
For analysis of tablet dosage form, twenty tablets, each containing 12.5 mg of Alogliptin and 
500mg of Metformin, were weighed and their average weight was calculated. The tablets 
were finely powdered and powder equivalent to 10 mg Alogliptin and 400mg Metformin 
were accurately weighed and dissolved in 10 mL of methanol. The solution was sonicated for 
30 min, filtered through the Whatman No. 41 filter paper and the residue was washed with 
methanol. This solution was further diluted with methanol to get the same concentration as 
that of the final standard solution. The chromatogram was shown in Fig.15. 
CHROMATOGRAM DEVELOPMENT  
Alogliptin and Metformin reference standard solutions were prepared using methanol as 
solvent. Solutions of 0.1-0.5 µL were applied to the HPTLC plates as spot bands of 6 mm 
using LINOMAT V. Application positions were at least 15 mm from the sides and 10 mm 
from the bottom of the plates. Mobile phase components were mixed prior to use and the 
development chamber was left for saturation with mobile phase vapor for 20 mins before 
each run. Development of the plate was carried out by the ascending technique to a migration 
distance of 7 cm. Then the plates were dried on a hot plate. All the analyses were carried out 
in a laboratory with temperature control (20–24ºC).  
DETECTION  
Densitometry scanning was done in absorbance mode at 254 nm using a deuterium lamp. The 
slit dimensions were set at 6 mm-0.30 mm, the scanning speed of 10 mm/s, and the data 
resolution at100 µm/step. Single wavelength detection was performed since the main 
components were only analyzed. 
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VALIDATION OF THE METHOD  
The developed method was validated as per the International Conference on Harmonization 
(ICH) guidelines with respect to linearity and range, specificity, precision, accuracy, limit of 
detection and limit of quantification. 
LINEARITY AND RANGE 
 A stock standard solution was prepared for both Alogliptin and Metformin they were serially 
diluted to yield five standard solutions. A volume of 0.1-0.5 µL of each solution was applied 
to the HPTLC plate to deliver 100, 200,300, 400 and 500 ng/spot of Alogliptin, 4000, 8000, 
12000, 16000 and 20000 ng of Metformin /spot. The calibration plots revealed good linear 
relationships between area and concentration over the range of 100-500 ng/spot for Alogliptin 
and 4000-20000 ng/spot for Metformin. The standard curves for Alogliptin and Metformin 
are shown in Fig.12 and Fig.13, respectively and data for both Alogliptin and Metformin is 
presented in Table 9 and 10.  
ACCURACY 
Accuracy of the method was determined by replicates (n=3) analysis, carried out using three 
solutions prepared by standard addition of pure active pharmaceutical ingredient at three 
different concentration levels 80%,100% and 120%. Accuracy was calculated by comparing 
the difference between the spiked value (theoretical value) and that actual found value. 
Results are presented in the tem of %recovery of the active pharmaceutical ingredient and 
data for both Alogliptin and metformin is presented in Table 5. 
LIMITS OF DETECTION AND QUANTIFICATION   
The limit of detection was found to be 2 ng/spot and 40 ng/spot for Alogliptin and 
Metformin, respectively. The limit of quantification was found to be 6 ng/spot and 130 
ng/spot for Alogliptin and Metformin, respectively, which was lower than that reported 
earlier. 
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PRECISION  
Precision of the method was demonstrated by  
a. Intraday precision  
b. Interday precision 
c. Repeatability  
 
a) Intraday Precision 
            Intra-day precision was found out by carrying  out the analysis of the standard drug at   
three different concentrations of 100,200and 300 ng for Alogliptin, 4000, 8000 and 
12000 ng for Metformin were selected from linearity range. Intraday analysis was 
carried on same day in three replicates. Each concentration was applied in duplicate 
and %RSD was calculated and the results shown in Table 6. 
b) Interday Precision 
      Inter-day precision was found out by carrying out the analysis of the standard drug at           
      three different concentration of 100,200and 300 ng for Alogliptin, 4000, 8000 and       
      12000 ng for Metformin were selected from linearity range. Interday analysis was  
      carried on three different days in three replicates. Each concentration was applied in  
      duplicate and %RSD was calculated and the results shown in Table 7. 
c) Repeatability 
      Repeatability was determined by applying 0.4 µL of standard solution containing       
      400 ng/spot of Alogliptin and 16000 ng/spot of Metformin in six replicates and  
      respective areas were calculated. The %RSD was calculated and the results are shown  
      in Table 8.  
  SPECIFICITY 
The chromatogram of the solution, which was not spiked with Alogliptin and Metformin, did 
not show any spot, while the chromatogram of the solution of the tablet matrix spiked with 
Alogliptin and Metformin showed clear, compact and well separated peaks of Alogliptin and 
Metformin Fig.14. Moreover, from Fig.14, it can be seen that no other peaks were eluted 
besides the two active compounds. The method was therefore considered to be specific. 
Different concentration of metformin and Alogliptin are analysed and the chromatogram was 
shown in Fig.16 to 20. The UV spectrum of metformin and Alogliptin and overlay are 
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analysed through winCATS software and spectrum shown in Fig.21 to 23.  The 3D 
chromatogram of metformin and alogliptin shown in Fig .24.  
ROBUSTNESS 
The robustness of an analytical method evaluates the method capacity to remain unaffected 
by minor but purposeful variations in the method parameter and provides an indication of its 
reliability during normal usage. Robustness of the developed method was evaluated by the 
analysis of sample solution after making small changes in the mobile phase volume and 
mobile phase saturation time. The low value of % RSD shows that the method is robust and 
that a slight change in mobile phase volume and mobile phase saturation time does not affect 
the results 
  Table.5: Accuracy for Alogliptin and Metformin  
Level % Recovery % RSD 
ALG MET ALG MET 
80 % 100 102.5 0.349 0.484 
100 % 98.87 100.24 0.375 0.440 
120 % 101.75 100.30 0.472 0.308 
 
   Table.6:  Intraday precision data for Alogliptin and Metformin (n=3) 
 
 
Level 
Concentration (ng/ml) Peak area % RSD 
ALG MET ALG MET ALG MET 
 
I 
 
 
200 
 
       8000 
585.3 12349  
0.43 
 
 
1.05 582.1 12566 
580.3 12329 
 
II 
 
300 
 
12000 
600.2 12449   
598 12226.5      0.61 1.03 
593 12229.5   
 
III 
 
 
400 
 
        16000 
500.8 12925.4  
1.04 
 
0.88 496.2 12966.6 
490.5 12751.7   
RSD Relative standard deviation 
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Table.7:  Interday precision data for Alogliptin and Metformin (n=3) 
 
 
 
Day 
Concentration (ng/ml) Peak area %RSD 
ALG MET ALG MET ALG MET 
1  
200 
 
       8000 
550 7142.5  
0.66 
 
 
0.91 2 553 7033.2 
3 546.2 7028.1 
1  
300 
 
12000 
600.5 10091.5   
2 596.3 10188      0.35 0.59 
3 598 10076   
1  
400 
 
        16000 
750.3 15996.3  
0.70 
 
0.30 2 746 15953.2 
3 756.5 15900.2   
RSD Relative standard deviation 
 Table.8: Repeatability data for Alogliptin and Metformin (n=6) 
 
Concentration Injection Peak area %RSD 
ALG MET ALG MET 
 
Alogliptin(0.4 µg) 
 
Metformin (16 µg ) 
1 1458.5 12745.1  
 
     0.82 
 
 
     1.03 
2 1443.0 12470.1 
3 1456.4 12365.4 
4 1435.6 12569.5 
5 1436.2 12458.9 
6 1428.1 12487.8 
    
RSD
 Relative standard deviation 
 
 
 
 
 
  
  
 
                                                Fig.12. Linearity curve of Alogliptin benzoate 
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               Table.9: Linearity data for alogliptin  
                  
                   
 
 
 
 
                
                              Fig.13. Linearity curve of Metformin hydrochloride 
    
           Table.10: Linearity data for Metformin 
 
 
 
 
 
 
 
 
 
 
 
y = 1.1122x - 2718.4
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Concentration ng/spot 
S.No Concentration (ng/spot) Peak area 
1 100 404.85 
2 200 600.23 
3 300 839.89 
4 400 1023.36 
5 500 1236.45 
S.No Concentration (ng/spot) Peak area 
1 4000 1634.24 
2 8000 6742.45 
3 12000 9921.56 
4 16000 15186.39 
5 20000 19656.81 
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Fig.14. Chromatogram for Alogliptin and Metformin at 254 nm in standard solution 
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Fig.15. Chromatogram for Alogliptin and metformin at 254 nm in formulation 
 
Chromatogram of all standards 
Fig.16.Concentration 1 (metformin: 4000 ng/ml and alogliptin: 100 ng/ml) 
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Fig.17. Concentration 2 (metformin: 8000 ng/ml and alogliptin: 200 ng/ml) 
 
Fig.18. Concentration 3 (metformin: 12000 ng/ml and alogliptin: 300 ng/ml) 
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Fig.19. Concentration 4 (metformin: 16000 ng/ml and alogliptin: 400 ng/ml) 
 
Fig .20.Concentration 5 (metformin: 20000 ng/ml and alogliptin: 500 ng/ml) 
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                    Fig.21. UV Spectrum of Alogliptin 
 
                       
     Fig.22. UV Spectrum of Metformin 
 
Fig.23.   Overlain UV spectrum of metformin and alogliptin 
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Fig.24. 3D Chromatogram of Alogliptin and Metformin  
 
 
 
 
 
 
 
                      Fig. 3D chromatogram of Alogliptin and Metformin 
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SIMULTANEOUS QUANTIFICATION OF METFROMIN AND ALOGLIPTIN IN 
HUMAN PLASMA (in-vitro) BY RP-HPLC METHOD 
1. SELECTION OF CHROMATOGRAPHIC METHOD   
Depending on the nature of the sample (ionic or neutral molecule), its molecular 
weight and solubility, chromatographic method is to be selected. The drugs are polar 
in nature so reverse phase chromatographic technique was selected for the present 
study. 
2. SELECTION OF WAVELENGTH 
From the UV spectra obtained for both the drugs, 237 nm was selected as the 
wavelength for the study. Fig.25. 
Fig.25: Overlain UV spectrum of Alogliptin and Metformin 
 
3. OPTIMIZATION OF  MOBILE PHASE 
a) Separation using Methanol (100%) 
Initially 100% methanol was tried as the mobile phase system, only Metformin 
gave a peak with fronting. But there was no Alogliptin peak (Fig.26). 
b) Separation using Methanol: Water 
When tried with slow introduction of aqueous phase with different ratios, 
Methanol: Water there was no Alogliptin peak (Fig.27). 
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c) Separation using Acetonitrile: Water 
Different ratios of Acetonitrile: Water was tried. In this mobile phase system also 
there was no Alogliptin peak. Compare to previous mobile phase Metformin gave 
very broad peak. So Methanol was selected as the organic phase for further studies 
(Fig.28).  
d) Separation using Potassium dihydrogen ortho phosphate buffer: Methanol  
Potassium dihydrogen ortho phosphate buffer: Methanol (80:20) pH was adjusted 
to 8 using 30% ammonia solution. In this optimization condition only, Alogliptin 
gave the peak. But the elution time is more. So different pH was tried. The 
objective of optimization was to get good symmetrical peaks, well resolved from 
each other.  
In a solvent system consist of Potassium dihydrogen ortho phosphate buffer: 
Methanol (50:50) pH 8.0 was adjusted using ammonia was fixed as the 
chromatographic condition for this study (Fig.29). 
                   PREPARATION OF MOBILE PHASE 
                   A mixture of methanol: 20 mM potassium dihydrogen ortho phosphate in water               
(pH-8) (50:50 v/v) was prepared. The pH was adjusted to 8 using 30 % ammonia 
solution. The resultant mobile phase was degassed in an ultra Sonicator for 15 
min. 
 
                   PREPARATION OF 20 mM POTASSIUM DIHYDROGEN ORTHO 
PHOSPHATE BUFFER 
  The phosphate buffer solution was prepared by 2.7218 g of potassium dihydrogen    
  ortho phosphate was dissolved in 1000 ml of purified water in clean and dry flask.    
  The mixture was sonicated for 20 min. 
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Fig.26. Methanol 100% 
 
 
 
 
 
 
 
 
 
Fig.27. Methanol: Water (20:80) 
  
Fig.28 Acetonitrile: Water (20:80) 
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Fig.29 : Potassium dihydrogen ortho phosphate: Methanol (50:50) 
 
OPTIMIZATION OF SEPARATION CONDITIONS 
Effect of ionic strength of potassium dihydrogen ortho phosphate buffer 
Different ionic strengths like 50 mM, 20mM were tried. The ionic strength of 50 mM 
peaks are not resolved and showing fronting. Good symmetric peaks were obtained with an 
ionic strength of 20mM and hence this strength was selected for further studies (Fig. 30, 31). 
Effect of mobile phase ratio 
Mobile phase system consisting of methanol and 20mM potassium dihydrogen ortho 
phosphate buffer in different ratios like (60:40), (80:20), (50:50) (%v/v) were tried. (Fig.32-
34). In ratio of (60:40) both the peaks merge into each other. In ratio of (80:20) peak showing 
more retention time. A ratio of (50:50) gave good symmetrical peak and hence this ratio was 
fixed. 
Effect of pH 
The mobile phase methanol and 20mM potassium dihydrogen ortho phosphate buffer  
in the ratio (50:50) was kept constant and the chromatogram of drug solution were recorded 
in different buffer pH ranging from 6-8.  Good symmetrical peaks were obtained at pH 8.0 
which was selected for further studies. (Fig.35-36). 
Effect of flow rate 
The chromatogram were recorded at different flow rates like 0.3, 0.5, 1.0 mL/min 
keeping the ratio of mobile phase and buffer pH constant. (Fig.37-39). At a flow rate 0.3 
mL/min the peaks are broad and tailing and flow rate 0.5 mL/min peaks resolution is more. 
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Hence a flow rate 1 mL/min which gave good symmetric peaks with resolution was selected 
for further studies. 
 
FIXED CHROMATOGRAPHIC CONDITIONS 
Stationary phase             :      Phenomenex Luna C18 (250 x 4.6 mm) 5 µm 
Mobile phase                   :    Methanol: 20mM potassium dihydrogen ortho phosphate   
      Buffer pH adjusted to 8 using ammonia                                                                                                                                                                                                             
Solvent ratio                    :      50:50v/v 
pH                                     :      8.0 
Detection wavelength     :      237 nm 
Flow Rate                        :      1.0 mL/min 
Retention time  
 Metformin           : 2.9 min 
 Alogliptin             : 7.1 min 
EFFECT OF IONIC STRENGTH OF POTASSIUM DIHYDROGEN PHOSPHATE 
BUFFER ON SEPARATION 
Fig. 30:  50mM potassium dihydrogen phosphate buffer 
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Fig.31: 20mM potassium dihydrogen ortho phosphate buffer 
 
EFFECT OF MOBILE PHASE RATIO 
Fig.32: (Methanol: potassium dihydrogen ortho phosphate buffer) 60:40
 
Fig 33: (Methanol: potassium dihydrogen ortho phosphate buffer) (80:20) 
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Fig .34.10:50:50 (Methanol: Potassium dihydrogen ortho phosphate buffer) (50:50) 
 
EFFECT OF PH ION SEPARATION 
Fig.35: pH 6.0 of potassium dihydrogen ortho phosphate 
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Fig.36. pH 8.0 of potassium dihydrogen ortho phosphate 
 
EFFECT OF FLOW RATE ON SEPARATION 
Fig .37: Flow rate 0.3 mL/min 
 
Fig38: Flow rate 0.5 mL/min 
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Fig.39: Flow rate 1.0 mL/min 
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The above developed HPLC method was utilized for in-vitro estimation of metformin and 
alogliptin from plasma. 
For extracting the maximum quantity of drug from plasma, the extraction procedure was to 
be optimized. The main parameters optimized were  
1. Extraction method 
2. Organic solvent for extraction  
SELECTION OF EXTRACTION METHOD 
 Plasma consists of interferents, which interferes with the quantification of drug. 
Hence the drug must be separated from interferents. Extraction methods are employed for 
removal of interfering substances as primary requirement the substances to be extracted must 
be soluble not only in aqueous biological media but also in a phase which is immiscible with 
water eg. Dimethyl formamide, Acetonitrile and Methanol. 
INITIAL EXTRACTION PROCEDURE  
 Metformin 200-520 µg/ml and 5-13 µg/ml of Alogliptin, 0.5 ml was pipette out and 
spiked into 0.5 ml of plasma in polypropylene tube (Torson’s). Then the tube was cyclomixed 
for 5 min. Then the 1 ml of methanol was added to the tube and centrifuged for 20 min at 
3000 rpm. Further supernatant liquids were collected in another eppendrof tube and 
supernatant was injected into the analytical column. The same procedure was followed for the 
acetonitrile and dimethyl formamide. But in methanol only the drugs gave good separation 
and symmetric peaks. So methanol used as extracting solvent for further studies. 
SELECTION OF ORGANIC SOLVENT FOR EXTRACTION 
 The extraction of drug into organic solvent depends on its distribution coefficient in 
aqueous and organic phases. Different solvents like dimethyl formamide, chloroform, 
acetonitrile, methanol etc. were tried. The drugs were not soluble in chloroform, acetonitrile. 
Based on the solubility and maximum extraction efficiency methanol was selected as solvent 
for extraction, (Fig. 40).  
FIXED EXTRACTION PROCEDURE 
     Metformin 200-520 µg/ml and 5-13 µg/ml of Alogliptin, 0.5 ml was pipette out and 
spiked into 0.5 ml of plasma in polypropylene tube (Torson’s). Then the tube was cyclomixed 
for 5 min. Then the 1 ml of methanol was added to the tube and centrifuged for 20 min at 
3000 rpm. Further supernatant liquids were collected in another eppendrof tube and 
supernatant was injected into the analytical column (Fig 41).  
PREPARATION OF STANDARD SOLUTION  
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 A stock solution was prepared by dissolving accurately weighed 10 mg of metformin 
and 1 mg of alogliptin in a 10 ml of methanol to yield a concentration of 1000 µg/ml of 
metformin and 100 µg/ml of alogliptin, respectively. The solution was sonicated for 20 min. 
Series of aliquots of drug solution containing 200 to 520 µg/ml of metformin and 5 to 11 
µg/ml of alogliptin were prepared. To each of five centrifuge tubes 0.5 ml of above prepared 
solutions was transferred. To this 0.5 ml of plasma was added and with 1 ml of extracting 
solvent of methanol was added to the tube and centrifuged for 20 min at 3000 rpm. Further 
supernatant liquids were collected in another eppendrof tube and supernatant was injected 
into the analytical column.  
PREPARATION OF SAMPLE SOLUTION  
Fixed dose working sample solutions were prepared according to dosage forms of kazano® 
tablets. Accurately weighed samples of kazano® contain 500:12.5 mg of metformin and 
alogliptin were transferred into 10 ml volumetric flask, dissolved in methanol and sonicated 
for 20 min and filtered the solution and from that aliquots solution are prepared. From the 
above prepared sample solution (metformin 200-520 µg/ml and 5-13 µg/ml of alogliptin), 0.5 
ml was pipette out and spiked into 0.5 ml of plasma in polypropylene tube (Torson’s). Then 
the tube was cyclomixed for 5 min. Then the 1 ml of methanol was added to the tube and 
centrifuged for 20 min at 3000 rpm. Further supernatant liquids were collected in another 
eppendrof tube and supernatant was injected into the analytical column. Calibration curve 
was plotted using peak area of standard drugs Vs concentration of standard solution. The 
peak area of the sample chromatogram compared and amount of metformin and alogliptin 
were calculated as shown in Table.11. The chromatogram was shown in Fig. 42.   
CHROMATOGRAM OF BLANK 
 Blank solution was prepared and chromatographed. It was found that there was no 
interference from blank plasma (Fig. 43). 
Table No.11 Analysis of formulation 
 S.No Drug Amount(mg) %Label claim %RSD* 
Labelled Found 
1 MET 500 428.43 85.68 1.2 
2 ALO 12.5 10.8 86.4 1.5 
*RSD of five observations 
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VALIDATION OF THE METHOD 
LINEARITY  
Calibration graphs were plotted following extraction procedure. The spiked samples of 
plasma were found to be linear in the concentration range from 200-520 µg/ml of metformin 
and 5-13 µg/ml of alogliptin. The final concentration was found to be in the linearity range of 
the drugs shown in (Fig. 44, 45) and the chromatogram was shown in (Fig. 46-50). The 
calculated statistical data are shown in Table 12, 13. 
PRECISION  
Precision of the method was demonstrated by  
1. Intraday precision 
2. Interday precision 
3. Repeatability 
Intraday precision 
Intraday precision was found by carrying out the analysis at three different concentrations in 
the linearity range for three times on the same day. % RSD was calculated and the results are 
represented in Table 14.   
Interday precision 
Interday precision was found by carrying out the analysis at three different concentrations in 
the linearity range for three days over a period of one week. % RSD was calculated and the 
results are represented in Table 15. 
Repeatability   
Standard solution of mixture of drug was injected five times and its % RSD was calculated 
and the results represented in Table 16. The chromatogram was shown in (Fig. 51). 
LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTIFICATION (LOQ) 
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LOD and LOQ were determined by injecting decreasing amounts of drug. The lowest 
concentration at which peak is determined is called LOD was found out to be 2 µg/ml for 
metformin and 0.5 µg/ml for alogliptin.  
The lowest concentration at which peak can be quantified is called LOQ was found to be for 
5 µg/ml Metformin and 1 µg/ml for Alogliptin.  
RECOVERY  
The extraction efficiency was explained by recovery studies. Various aliquots of 
concentration of standard were added to fixed concentration of sample and analysed 
following the extraction procedure described earlier and amount was calculated. % RSD was 
calculated and the results are represented in Table 17.  The chromatogram was shown in 
(Fig. 52-53). 
SYSTEM SUITABILITY STUDIES 
System suitability parameters like plate number, peak asymmetric factor, capacity factor, 
selectivity factor, resolution factor are calculated with the help of standard chromatogram 
Table 18. 
PEAK PURITY TEST 
Peak purity test was performed for the standard drug peaks. Peak purity index values of   
metformin and alogliptin were found to be 0.9996, 1.0000 respectively. Values close to one 
indicate the purity of the peaks. 
Fig.40 Chromatogram for metformin and alogliptin in acetonitrile 
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Fig.41 Chromatogram for metformin and alogliptin in methanol 
 
Fig.42 Chromatogram for formulation 
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Fig.43 Chromatogram for blank 
 
Fig.44  Calibration curve of Metformin 
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Table 12: Statistical data of the regression equation for Metformin 
Parameters Metformin 
Linearity range(µg/mL) 200-520 
Coefficient of correlation 0.996 
Slope 20808 
Y-intercept 48974 
 
Concentration(µg/mL) Peak area 
200 4572766 
280 6332815 
y = 20808x + 489741
R² = 0.9962
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360 7988601 
440 9894137 
520 11115454 
 
Fig.44 Calibration curve of Alogliptin  
 
 
 
 
 
Table 13: Statistical data of the regression equation for Metformin 
Parameters Alogliptin 
 
Linearity range(µg/mL) 5-13 
Coefficient of correlation 0.987 
Slope 5565 
Y-intercept                           6715 
 
Concentration(µg/mL) Peak area 
5 20803 
7 32379 
y = 5565.5x - 6715.3
R² = 0.9993
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9 43479 
11 55122 
13 65086 
 
Chromatogram of all standards  
Fig. 46 Standard 1:  
 
 
 
 
Fig. 47 Standard 2: 
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Fig. 48 Standard 3: 
 
 
 
 
 
 
Fig. 49 Standard 4:  
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Fig. 50 Standard 5: 
 
 
 
 
 
 
 
 
Fig. 51 Repeatability for Metformin 
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Fig. 52 Repeatability for Alogliptin 
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Fig. 53 Recovery for Metformin and Alogliptin
 
Table 14: Intra-Day precision 
Level Concentration(µg/mL) Peak area %RSD 
MET ALO MET ALO MET ALO 
I 280 7 
657437 35275  
0.63 
 
0.72 
650035 34923 
658090 35421 
II 360 9 
726644 41248  
0.49 
 
0.32 720033 41023 
725832 41009 
III 440 11 
943750 53750 
 
0.14 
 
0.79 
945200 53200 
942520 52920 
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Table 15: Inter-Day precision 
Day Concentration(µg/mL) Peak area %RSD 
MET ALO MET ALO MET ALO 
1 
 
280 
 
7 
675569 25301 
0.33 0.71 2 678567 24981 
3 680004 25003 
1 
360 9 
801534 35701 
0.38 0.46 2 805051 35981 
3 798845 35998 
1 
440 11 
999988 49821 
0.68 0.10 
2 988985 49881 
3 987643 49781 
 
Table 16: Repeatability of injection 
Concentration 
(µg/mL) 
 
Injection 
Peak area %RSD 
MET ALO MET ALO MET ALO 
 
 
 
200 
 
 
 
5 
1 
3332314 19742 
 
 
 
0.78 
 
 
 
0.48 
2 
3280696 19525 
3 
3332354 19652 
4 
3344789 19555 
5 
3303875 19712 
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Table 17. Recovery studies 
S.No Level % Recovery % RSD* 
MET ALO MET ALO 
1 80% 98.94 98.9 1.41 0.80 
2 100% 101.23 100.6 1.20 0.61 
3 120% 99.4 99.78 1.32 0.72 
*RSD of three observations 
 
Table 18. System suitability studies 
Drug Rs N Α 
Metformin 1.72 4050.5 1.8 
Alogliptin 1.4 3820.7 0.75 
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RESULTS AND DISCUSSION 
The present study was to develop a well validated, sensitive, simple and quick analytical 
method for the simultaneous determination of metformin and alogliptin in pharmaceutical 
formulation. 
      UV spectroscopic method, high performance thin layer chromatographic method was 
developed for the estimation of metformin and alogliptin in pharmaceutical dosage form. 
High performance liquid chromatographic method was developed for the estimation of 
metformin and alogliptin in pharmaceutical dosage form and plasma. 
      In UV spectroscopic method for the estimation of this combination, methanol was 
selected as the solvent. The detection wavelength selected was 237 nm for metformin and 
225 nm for alogliptin. Linearity showed good linear relationship over a concentration range 
of 2-10 µg/ml for metformin and the correlation coefficient value was found to be 0.999 for 
both wavelength and 0.05–0.25 µg/ml for alogliptin and the correlation coefficient value was 
found to be 0.933 at 237 nm and 0.996 at 225 nm, respectively. It indicates good correlation 
between the response factor and concentration. The developed method was validated in terms 
of accuracy, precision and stability. The formulation was extracted with methanol a diluted to 
get concentration in between the linearity range. Absorbance values were used to determine 
the amount of drugs in formulation. The drug solution was found to be stable for about 3 
hours in room temperature. The results of recovery are represented in Table 4.  
        Estimation of metformin and alogliptin by HPTLC method, methanol was used as the 
solvent. The wavelength of 254 nm was selected. Mobile phase system consisting of 
chloroform: methanol: 0.5% ammonium sulphate in the ratio of 4:4:2 % v/v was selected. Rf 
value of metformin and alogliptin were found to be 0.44 ±0.02, 0.66±0.02, respectively. 
The linearity was found to be in the range of 4000- 20000 ng/spot for metformin and 100 – 
500 ng/spot for alogliptin, respectively. The correlation coefficient value (0.99) close to 1 
proves the linearity. The slope and intercept value were found to be 2.086 and 195 for 
metformin and 1.112 and 2718 for alogliptin, respectively. The LOD and LOQ was found to 
be 40 ng/spot and 130 ng/spot for metformin and 2 ng/spot and 6 ng/spot for alogliptin, 
respectively. Validation parameter like precision, accuracy and stability were carried out and 
the low % RSD value indicated that the method was good and reproducible. The analyte was 
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found to be stable for 3 hours. Recovery studies were performed at 80 %, 100 % and 120 % 
and results are represented in Table 5. 
 
      Metformin and alogliptin were estimated in plasma by RP-HPLC method. Optimization 
of chromatographic parameters was carried out by RP-HPLC. Parameters such as selection of 
chromatographic method for separation, effect of ratio of mobile phase, effect of pH of 
mobile phase and effect of flow rate were optimised. A mobile phase system consisting of 
potassium dihydrogen ortho phosphate : methanol was used with the wavelength 237 nm. A 
mixture of 20 mM potassium dihydrogen ortho phosphate buffer and various ionic strengths 
of potassium dihydrogen ortho phosphate such as 20 mM and 50 mM were subjected and 
ionic strength of 20 mM was selected and with 20 mM strength various ratio of mobile phase 
such as 60:40, 80:20 and 50:50 % v/v was carried out and the ratio of 50:50 was selected. 
With the above said ratio various buffer pH from 6 and 8 were carried out and pH 8 was 
selected. Different flow rates were carried out with constant of above mentioned parameters 
and flow rate of 1 ml/min was selected. 
       The developed HPLC method was used for the estimation of the combined drugs by in-
vitro method. Different extraction solvents were tried like acetonitrile, dimethylformamaide 
and methanol. Extraction efficient is good in methanol. So methanol is selected as the 
solvent. Different concentration of drug is spiked with plasma and then the tube was 
cyclomixed for 5 min. Then the 1 ml of methanol was added to the tube and centrifuged for 
20 min at 3000 rpm.  The linearity range is 200-520 µg/ml for metformin and 5- 13 µg/ml for 
alogliptin in plasma, respectively. Extraction method is followed for formulation also. 
Retention time of metformin and alogliptin were found to be 2.9 and 7.1 min, respectively. 
Calibration curve was plotted using peak area of standard drugs Vs concentration of standard 
solution. The peak area of the sample chromatogram compared and amount of metformin and 
alogliptin were calculated as shown in Table 11. Significant percentage of recovery was 
observed which shows extraction efficiency of the method.   
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SUMMARY AND CONCLUSION 
In this study metformin and alogliptin in combined dosage form was estimated by proposed 
UV, HPTLC and RP-HPLC method. The main advantages of the proposed methods are its 
suitability and routine determination of these drugs in combined dosage form. 
The fixed dose combination tablet of metformin and alogliptin was subjected to simultaneous 
estimation by UV spectroscopic method. Compare with the available method, the developed 
method only analyzed the fixed dose tablet by UV simultaneous equation method. The 
proposed methods were validated by evaluation of the validation parameters. Assay was 
performed within a short analysis time.  
A new HPTLC method for the simultaneous determination of metformin and alogliptin in 
pharmaceutical tablet formulation has been developed. The method was found to be sensitive 
and specific for quantification of metformin and alogliptin in pharmaceutical formulation. 
The proposed method can be used in detail stability studies of metformin and alogliptin.  
The developed HPLC method was used for the estimation of the combination drugs in plasma 
by In-vitro method. Extraction efficiency was determined by the significant recovery studies. 
The method can be applied for toxicological, bio equivalence, therapeutic drug monitoring 
studies.      
From the forgoing it’s concluded that the methods developed are simple, rapid, selective and 
precise. Hence suitable for application in routine analysis of pharmaceutical preparation and 
from plasma. 
 
 
 
Drug 
 
RP-HPLC 
 
 
HPTLC 
 
UV 
% 
Recovery 
 
Linearity 
% 
Recovery 
 
Linearity 
% 
Recovery 
 
Linearity 
 
Metformin 
 
99.85 
 
200-520 
µg/ml 
 
101.01 
 
4000-20000 
ng/ml 
 
99.82 
 
2-10 
µg/ml 
 
Alogliptin 
 
99.76 
 
5-13 
µg/ml 
 
100.20 
 
100-500 
ng/ml 
 
98.80 
 
0.05-0.25 
µg/ml 
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